University of Pennsylvania

ScholarlyCommons
Publicly Accessible Penn Dissertations

1-1-2014

Effect of Cyclosporin a on the Tumor
Microenvironment
Yao Zhou
University of Pennsylvania, zhouyao@mail.med.upenn.edu

Follow this and additional works at: http://repository.upenn.edu/edissertations
Part of the Cell Biology Commons, and the Medicine and Health Sciences Commons
Recommended Citation
Zhou, Yao, "Effect of Cyclosporin a on the Tumor Microenvironment" (2014). Publicly Accessible Penn Dissertations. 1526.
http://repository.upenn.edu/edissertations/1526

This paper is posted at ScholarlyCommons. http://repository.upenn.edu/edissertations/1526
For more information, please contact libraryrepository@pobox.upenn.edu.

Effect of Cyclosporin a on the Tumor Microenvironment
Abstract

Tumor angiogenesis is a hallmark of cancer, and plays a critical role in tumor growth, expansion, and
metastasis. Both physiological and pathological angiogenesis is assumed to be regulated by the balance
between pro and anti-angiogenic factors. One of the best characterized and most potent pro-angiogenic
regulators is vascular endothelial growth factor, or VEGF. Calcineurin signaling is an important mediator of
VEGF signaling in endothelial cells. Negative regulation of calcineurin by increased expression of its
endogenous inhibitor, Down Syndrome Candidate Region-1 (DSCR1), suppresses tumor growth and
angiogenesis. However, a potent pharmacological calcineurin inhibitor, the commonly used
immunosuppressant cyclosporin A (CsA), significantly increases the incidence of cancer in organ transplant
recipients. The mechanism by which CsA promotes cancer in this patient population is not well understood
and despite the significance of calcineurin signaling in endothelial cells, the consequences of CsA on tumor
angiogenesis has not been investigated. Using an in vivo model of skin carcinogenesis, we show that long-term
CsA treatment promotes tumor growth and angiogenesis. Further our data indicate that treatment of
endothelial cells in vitro with CsA increases proliferation and migration, in a calcineurin-independent manner.
Our studies reveal that CsA-induced endothelial cell activation was due to the interaction of CsA with
cyclophilin D located on the mitochondrial inner membrane. CsA treatment in endothelial cells increased
mitochondrial membrane potential and mitochondrial reactive oxygen species production, and was associated
with sustained mitogen-activated protein kinase (MAPK) activity. Co-treatment with antioxidants
significantly abrogated CsA-induced endothelial cell activation. Furthermore, mice treated with antioxidants
were protected against CsA-mediated tumor progression. Taken together, these findings show that CsA
functions independent of calcineurin to potentiate tumor growth by promoting tumor angiogenesis via
mitochondrial reactive oxygen species production. This work identifies a previously undescribed mechanism
underlying a significantly adverse off-target effect of CsA and suggests that co-treatment with antioxidants
may inhibit the tumor promoting effects of CsA.
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ABSTRACT
EFFECT OF CYCLOSPORIN A ON THE TUMOR MICROENVIRONMENT
Alice Yao Zhou
Sandra Ryeom

Tumor angiogenesis is a hallmark of cancer, and plays a critical role in tumor growth,
expansion, and metastasis. Both physiological and pathological angiogenesis is assumed
to be regulated by the balance between pro and anti-angiogenic factors. One of the best
characterized and most potent pro-angiogenic regulators is vascular endothelial growth
factor, or VEGF. Calcineurin signaling is an important mediator of VEGF signaling in
endothelial cells. Negative regulation of calcineurin by increased expression of its
endogenous inhibitor, Down Syndrome Candidate Region-1 (DSCR1), suppresses tumor
growth and angiogenesis. However, a potent pharmacological calcineurin inhibitor, the
commonly used immunosuppressant cyclosporin A (CsA), significantly increases the
incidence of cancer in organ transplant recipients. The mechanism by which CsA
promotes cancer in this patient population is not well understood and despite the
significance of calcineurin signaling in endothelial cells, the consequences of CsA on
tumor angiogenesis has not been investigated. Using an in vivo model of skin
carcinogenesis, we show that long-term CsA treatment promotes tumor growth and
angiogenesis. Further our data indicate that treatment of endothelial cells in vitro with
CsA increases proliferation and migration, in a calcineurin-independent manner. Our
studies reveal that CsA-induced endothelial cell activation was due to the interaction of
CsA with cyclophilin D located on the mitochondrial inner membrane. CsA treatment in
v

endothelial cells increased mitochondrial membrane potential and mitochondrial reactive
oxygen species production, and was associated with sustained mitogen-activated protein
kinase (MAPK) activity. Co-treatment with antioxidants significantly abrogated CsAinduced endothelial cell activation. Furthermore, mice treated with antioxidants were
protected against CsA-mediated tumor progression. Taken together, these findings show
that CsA functions independent of calcineurin to potentiate tumor growth by promoting
tumor angiogenesis via mitochondrial reactive oxygen species production. This work
identifies a previously undescribed mechanism underlying a significantly adverse offtarget effect of CsA and suggests that co-treatment with antioxidants may inhibit the
tumor promoting effects of CsA.
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CHAPTER 1: INTRODUCTION
Angiogenesis

Physiological angiogenesis
The circulatory system provides multi-cellular organisms with oxygen, nutrients,
and signaling molecules necessary for growth and homeostasis. Vertebrate vasculature is
defined as a closed system of elastic arteries that distribute blood to distant tissues,
capillary beds where gas exchange occurs, a venous system that returns deoxygenated
blood, and a muscular pump that moves the blood through at a rate adaptive to the
metabolic demands of the organism. This mode of nutrient and oxygen delivery has been
conserved with relatively few changes throughout evolution (Axnick & Lammert 2012).
Developmentally, the vertebrate vascular system appears early on in
embryogenesis, starting in the primitive streak. Endothelial precursors develop into a
primary plexus, dorsal aorta, and the cardinal vein, before joining together to form the
preliminary circulatory system. The de novo formation of vessel from endothelial
precursors early in development is termed vasculogenesis (Jain 2003). In addition to
providing a rudimentary circulatory system for the developing embryo, vasculogenesis
also plays a role in shaping organogenesis and has been shown to provide trophic signals
for liver, pancreatic, and kidney development (Coultas et al. 2005).
Once a primitive vascular template has been established through vasculogenesis,
the vascular plexus expands and grows into a mature circulatory system by means of
1

vascular sprouting and remodeling from existing vessels, a process known as
angiogenesis (Jain 2003) which is responsible for the majority of vascular development.
Angiogenesis is a tightly regulated process that continues throughout development, with
increasing interactions and specificity towards the organ systems it supplies.
The angiogenic process can be roughly separated into four stages: initiation of
sprouting, sprouting outgrowth, sprout fusion / lumen formation, and stabilization/
maturation of the vessel (Jain 2003; Carmeliet 2000) (Fig 1.1.). These stages are
contiguous with one another and are tightly regulated by pro and anti-angiogenic
regulators to ensure proper vessel growth. This process is most prominent in fetal
development, but also occurs later in life during physiological and pathological
angiogenesis in adults (Carmeliet 2005).
The first step of angiogenesis is the stimulation of angiogenic growth that is
primarily mediated by the secreted vascular endothelial growth factor A (VEGFA), a
critical pro-angiogenic molecule. VEGFA is part of a large family of angiogenic
regulators that include VEGFB, VEGFC, VEGFD, and placental growth factor (PlGF)
(Coultas et al. 2005) (Table 1.1). The predominant effect of VEGFA on nascent
endothelial cells is to promote migration, proliferation, and differentiation. The effect of
VEGFA on developing vessels is regulated by various splice variants and receptor
signaling such as the anti-angiogenic β-isoform VEGFA splice variant and the decoy
receptor VEGFR1, which sequesters VEGFA with minimal angiogenic signaling effects
(Adams & Alitalo 2007) (Table 1.2). Chemotactic gradients, formed from pro- and

2

inhibitory signals, select individual endothelial cells to sprout from the parent vessel.
Sprouting endothelial cells actively degrade extracellular matrix in the migratory front,

Fig. 1.1. Overview of physiological angiogenesis. (A) Activation of endothelial cells
through chemotactic gradients, followed by (B) migration through the vascular
smooth muscle cell barrier and proliferation, guided by pro- and anti-angiogenic
signals. (C) The vessel continues to elongate and may fuse with another growing
vessel before (D) excessive vessels are pruned, lumen formation finalizes, and
vascular smooth muscle cells are recruited.
3

change their apical-basal cellular polarity, and laterally inhibit neighboring endothelial
Table 1.1 VEGF family members. Bolded terms indicate dominant form or effect
Ligand
Size – isoforms
Expression
Receptor Effect on
angiogenesis
VEGFA
VEGFR1
Pro-angiogenesis
VEGF-A
121 (soluble)

VEGF-B
VEGF-C

VEGFA165 (intermediate
solubility) VEGFA165b (inhibitory)
VEGFA189 (heparin bound)
VEGFA206 (heparin bound)
VEGFB167 (heparin bound)
VEGFB186 (soluble)
VEGFC (29/31kDa – unprocessed)
VEGFC (21kDa – processed)

VEGF-D
PlGF

PlGF131
PlGF152 (heparin bound)
PlGF203
PlGF224 (heparin bound)

VEGFR2
NPR1

Muscle
Myocardium
Brown fat
Fetus:
Lymph vessels
Fetus: lung, skin
Placenta
Retina
Heart
Lung

VEGFR1
NP1
VEGFR2
VEGFR3
VEGFR2
VEGFR3
VEGFR1
NP1

Table 1.2 VEGF receptors. Bolded terms indicate dominant effect.
Receptor Alternativ Ligand
Expression
Pairing
e forms
Partner
Soluble
VEGFA
endothelium,
VEGFR1
VEGFR1
VEGFR1
VEGFB
osteoblasts,
VEGFR2
(Flt-1)
(inhibitory)

PlGF

VEGFR2
(KDR/Fl
k-1)

VEGFA
VEGFC
VEGFD

VEGFR3
(Flt-4)
NP1

VEGFC
VEGFD

NP2

Soluble
NP1
(inhibitory)

macrophages, renal
cells, hematopoietic
stem cells (HSC),
placenta trophoblasts
endothelium,
neurons, osteoblasts,
megakaryocytes and
HSC
Lymphatic
endothelial cells

VEGFR1
VEGFR2
VEGFR3
VEGFR2
VEGFR3

VEGFA165
VEGFB
and PlGF

arterial endothelium,
lung, heart, liver,
kidney, pancreas,
bone marrow

VEGFR2

VEGFA,
VEGFC
and PlGF

lymphatic, venous
endothelium, lung,
heart, liver, kidney,
pancreas, bone
marrow

VEGFR2
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↑ Permeability
Bone turnover
Monocyte chemokine
HSC mobilization
Unclear
Weakly mitogenic
Lymphangiogenesis
Angiogenesis and
lymphangiogenesis
Placental, ovarian,
and retinal
angiogenesis

Signaling
Outcome
+VEGFR2 = weak
angiogenesis
+VEGFR1 =
inhibitory
Soluble VEGFR1 =
decoy receptor
VEGFR2
homodimerization
major mediator of
angiogenesis
Lymphangiogenesis
Enhances VEGFAVEGFR2 signaling
Soluble
NP1=decoy
receptor
Unclear

cells from undergoing the same process. Interplay between the Notch-delta ligand like 4
(DLL4) and the VEGFA-VEGFR signaling plays a crucial part in this sprouting process
(Adams & Alitalo 2007; Jain 2003). Tip cell selection is not completely understood, but
is thought to be due to small differences in VEGFR2 expression or VEGFA in the local
environment along with crosstalk with Notch signaling (Blanco & Gerhardt 2013).
The establishment of tip cells is closely associated with the conversion of cells
immediately behind the tip cell into stalk cells, which follow the tip cells as the sprout
extends outwards, and proliferate to lengthen the nascent vessel. Stalk cells will
proliferate in response to guidance by the tip cell, which itself does not divide. Tip cell
maintenance, like in sprout selection, is thought to be due to interplay between the NotchDLL4 and VEGFA-VEGFR pathways, with increased expression of both in tip cells
(Adams & Alitalo 2007).
When the budding vessel encounters existing capillaries or other growing
endothelial sprouts, it establishes adhesive cellular junctions to fuse with the encountered
vessel. Inappropriate junction formation is prevented by various adhesive and repulsive
signals. Upon fusion with another vessel, the newly developed vessel then lumenizes to
allow for eventual fluid flow (Adams & Alitalo 2007). This lumenization process is
poorly understood, but recent evidence shows it occurs through ‘cord hollowing’ where a
cylindrical column of cells drastically reshape around a hollow core to form a
multicellular lumenized tube (Nelson & Beitel 2009).
Naked endothelial cells that constitute newly formed vessels are unstable and
leaky and require stabilization through pericyte coverage. Pericytes and the closely
5

related vascular smooth muscle cells are contractile, mesenchymal cells that regulate
vessel contraction or dilation, permeability, and immune cell infiltration. In the
developing vessel, platelet derived growth factor (PDGF), secreted by endothelial cells,
recruits and attracts pericytes. Subsequent pericyte coverage and stabilization of the
vessel is, in part, regulated by the Angiopoietin-Tie2 system. Pericyte-derived soluble
molecule angiopoietin 1 (Ang-1) promotes endothelial cell survival and mural cell
attachment through binding to Tie-2 receptors on endothelial cells. Negative regulators
such as angiopoietin 2 (Ang-2), which also binds Tie-2 receptors, act to antagonize vessel
stability and work in conjunction with Ang-1 to prune and guide vessel formation and
maturation (Jain 2003).
Angiogenesis is an active process that occurs largely during development. Once
the vascular network have been formed and stabilized, it remains relatively static
throughout life. Second only to cells in the nervous system, endothelial cells are one of
the longest-lived cells in the body (Bergers & Benjamin 2003). Angiogenesis in
adulthood is an infrequent event and occurs in response to a precipitating incident such as
wound healing, endometrial growth during the menstrual cycle, or placental growth
during pregnancy (Carmeliet 2005). When it does occur, physiological angiogenesis in
adults is also tightly regulated and follows the same steps and pathways as in
developmental angiogenesis.

6

Pathological angiogenesis
While physiological angiogenesis in adults is a rare event, many pathological
conditions feature dysregulated vessel growth. In preeclampsia and ischemic heart
disease, the angiogenic response is insufficient to meet metabolic needs, resulting in
inadequate tissue perfusion. In the majority of disease states involving pathological
angiogenesis the angiogenic switch is inappropriately activated, leading to aberrant vessel
formation. While pathological angiogenesis occurs through a similar fashion as
physiological angiogenesis, the tightly controlled factors and temporal steps that result in
functional vessels are dysregulated, and vessel maturation in particular, is absent or
abnormal in the disease state. The predominant pathological conditions that involve
aberrant angiogenesis are either inflammatory or malignant.

Diabetic retinopathy
The retina has a highly regulated and organized vascular anatomy to balance
perfusion with light detection. Areas of high photoreceptor density such as the fovea,
have greatly decreased vascularization (Gariano & Gardner 2005). Pathological retinal
angiogenesis that occurs in diabetes is the leading cause of irreversible vision impairment
and blindness in adults. Diabetic retinopathy occurs in 20% of patients with diabetes, a
systemic metabolic and inflammatory disease, and is characterized by microaneurysms
and exudative changes in the retinal vessels, areas of ischemia, abnormal vessel growth,
friable vessels, and hemorrhages (Gariano & Gardner 2005; Gardner 2012). This process
is progressive, occurring over years, and is dependent on the overall metabolic health of
7

the individual. Untreated, visual acuity will progressively decline and, in severe cases,
marked by episodic events of hemorrhaging or retinal detachment (Gardner 2012). As the
major inducer of angiogenesis, VEGFA plays a significant role in diabetic retinopathy. In
combination with inflammatory cytokines and chemokines, accumulation of VEGFA in
the vitreous humor results in increased vascular permeability of existing vessels and
initiates the formation of new vessels (Gariano & Gardner 2005). However, pericyte
coverage of the newly formed vessels is low, which in combination with pericyte loss
from existing vessels, results in weak and unstable retinal vasculature that dilate and leak.
This abnormal vessel growth paradoxically produces hypoxic conditions in the vitreous,
which induces the hypoxia inducible factor (HIF) to further upregulate pro-angiogenic
responses (Gariano & Gardner 2005). The most common treatment for diabetic
retinopathy involves vessel ablation by laser treatment, which prevents hemorrhages and
decreases exudate, but is a symptomatic treatment at best. Single target anti-angiogenic
therapies with anti-VEGF treatments have shown only partial success, as diabetic
retinopathy is complicated by the involvement of inflammatory molecules which also
affects vessel function (Gardner 2012). Therefore, the development of anti-angiogenic
treatments for diabetic retinopathy is still an area of active research.

Exudative age-related macular degeneration
The second most common cause of blindness in the elderly is age-related macular
degeneration (AMD), an inflammatory disease confined to the retina. As the name
implies, macular degeneration is the progressive and selective loss of vision in the macula,
8

or center of the visual field. This disease occurs in two types, dry/non-exudative AMD,
characterized by plaque-like formations called drusden, and wet/exudative AMD, a more
severe form characterized by neovascularization. As with diabetic retinopathy, the newly
formed vessels associated with wet AMD is dysfunctional, leaky, and fragile, causing
functional impairment of the retina and can lead to retinal detachment (Rattner &
Nathans 2006). Previously, clinical management of wet AMD consists of symptom relief
through laser ablation therapy. In recent years, treatment options have improved due to
the use of anti-VEGF therapy to staunch the growth of new vessels (Dadgostar &
Waheed 2008). Injections of anti-VEGF antibodies such as Bevacizumab and
Ranibizumab directly into the retinal space have not only slowed the progression of
disease but also significantly improved vision, and is now the gold standard treatment for
wet AMD (CATT Research Group 2011; Dadgostar & Waheed 2008).

Tumor angiogenesis
Perhaps the most diverse and heterogeneous example of pathological
angiogenesis is tumor angiogenesis. The vascular requirement of solid tumors was first
recognized in the early 1970s by Judah Folkman. Given the rogue nature of tumor growth,
perfusion of a solid malignant growth can be a rate-limiting step for its expansion. The
importance of angiogenesis for malignant progression is reflected in its inclusion as one
of the original six hallmarks of cancer (Hanahan & Weinberg 2000).
Neoplastic angiogenesis is varied and heterogeneous depending on tumor type,
tumor stage, and other microenvironment cues. It is, however, almost always
9

disorganized, tortuous, and inefficient. Tumor vasculature does not follow hierarchical
divisions that mark normal vasculature such as arteries, capillary beds, and veins, with
hemodynamic considerations. Instead, neoplastic vessels are irregularly shaped and
dilated, with little or no distinction between arterioles, venules, or capillaries. Vessel
anastomosis may be abnormal or absent, explaining the presence of dead-end vessels.
Due to the chaotic nature of tumor vessels, perfusion is often poor with areas of
hemostasis or even reversal of flow. In addition to abnormal structure, the vessel itself is
often vastly haphazard and irregular with variable cellular organization and improper cell
junctions. These vessels display patchy and irregular mural cell coverage which, when
present, is also abnormal and dysfunctional. In combination with irregular hemodynamics,
these erratic vessels with poor vessel structure are often leaky, exudative, and
paradoxically under-perfused (Bergers & Benjamin 2003). Due to the dysfunctional
nature of neoplastic vessels and continuous remodeling that occurs in tumor vessels,
tumor perfusion can range from very hypoxic to very oxygenated, and can vary spatially
and temporally (Bergers & Benjamin 2003). The tumor microenvironment is a harsh and
variable environment; therefore, cancer cells that survive in this environment often have
decreased metabolic and oxygen demands, enabling them to survive within the inefficient
vascular network.
As a tissue expands, it outgrows its oxygen and nutrient supply and becomes
hypoxic, at which point hypoxia-responsive genes, regulated by HIF, are upregulated.
Growing tumor tissue, under the duress of hypoxia, secretes pro-angiogenic factors, the
most notable being VEGFA, but also can include fibroblast growth factor (FGF), placenta
10

induced growth factor (PIGF), and transforming growth factor-β (TGF-β). VEGFA alone
is able to initiate the angiogenic response, promoting sprouting from nearby vessels.
Since tumor growth is not organized or patterned, its promotion of angiogenesis is
similarly disorganized due to a misbalance between pro and anti-angiogenic factors
(Hickey & Simon 2006; Bergers & Benjamin 2003). While pericyte coverage in tumor
vasculature is found to be variable depending on the tumor subtype and the study
methods, the general consensus is that they are abnormal and dysfunctional (Raza et al.
2010). Tumor associated pericyte-like cells have weak endothelial cell contacts, and have
been shown to secrete VEGF, further aggravating vessel growth and leakiness (Raza et al.
2010; Bergers & Benjamin 2003).
The angiogenic process is a tight balance of pro and anti-angiogenic regulators. In
physiological angiogenesis, endogenous anti-angiogenic proteins help guide and structure
new vessel growth, as well as maintain vascular quiescence and prevent excessive growth.
Endogenous anti-angiogenic proteins originate from multiple sources; many are derived
from extracellular matrix proteins, others are inflammatory molecules, and some are
soluble decoy receptors (Folkman 2004). The extracellular matrix and stroma
surrounding existing vessels exert multiple layers of control and regulation in vessel
growth. As angiogenesis is a rare event in adult vasculature, the stromal environment
strongly inhibit angiogenesis, and cleaved fragments of many extracellular matrix
proteins, such as endostatin from collagen XVIII and tumstatin from collagen IV
(O’Reilly et al. 1997; Maeshima et al. 2000), act to inhibit new vessel growth.
Inflammatory molecules such as IFN-α, IL-1, IL-4, and IL-8 have also been shown to
11

have anti-angiogenic properties (Ribatti 2009). Endostatin, angiostatin, and
thrombospondin are the best characterized endogenous anti-angiogenic factors. Loss of
these factors, as in thrombospondin-1 null mice, results in accelerated tumor growth with
increased angiogenesis (Good et al. 1990). Therefore, endogenous anti-angiogenic factors
act as a natural defense system against pathological angiogenesis. Several drugs
exploiting these endogenous anti-angiogenic factors have shown promise in clinical trials.
For example, endostatin, in combination with chemotherapy, showed efficacy in several
clinical trials (Rong et al. 2012). The use of these drugs, however, is complicated by the
high dose needed, short half-life, repeated administration, and potential toxicities. While
they have potential for treating solid cancers, more pharmacological and clinical studies
are needed.

Anti-angiogenic therapy
The neovascular requirement of solid tumors opens a promising field for the
development of new anti-cancer drugs that target angiogenesis. A common
misunderstanding of anti-angiogenic therapy is that it serves only to cause vessel
regression, starving the tumor of oxygen and preventing tumor progression. While this
does occur, anti-angiogenic therapy has also been shown to cause vessel normalization
(Carmeliet & Jain 2011). Tumor vessels are inefficient in delivering oxygen and nutrients,
and in the setting of treatment, chemotherapeutic drugs. Therefore, in combination with
chemotherapeutic treatment, improving tumor vessel function actually results in better
drug delivery to the intended tissue (Carmeliet & Jain 2011). Therapies that target tumor
12

vessels are focused on vessel maturation and stabilization. VEGF withdrawal occurs in
the maturation stages of physiological angiogenesis and contributes to endothelial cell
quiescence. In line with this, multiple anti-angiogenic therapies were put into clinical trial
with the intent of vessel normalization, better drug delivery, and ultimately tumor
regression. In targeting the VEGF pathway, several anti-angiogenic drugs have been
developed: bevacizumab is a ligand-trapping monoclonal antibody, sorafenib and
sunitinib are kinase inhibitors that inhibit VEGFR2 (Bergers & Hanahan 2008).
Given the complexity of angiogenesis, its dysregulation in tumor angiogenesis,
and the mutational propensity of cancer cells, it is not surprising that anti-angiogenic
therapy has been clinically disappointing. While clinical trials utilizing anti-angiogenic
therapies initially showed promise with tumoristatic activity and rare tumoricidal activity,
most, if not all anti-angiogenic therapies eventually fail with tumor progression and
growth (Bergers & Hanahan 2008; Weis & Cheresh 2011). This has been attributed to a
number of resistance mechanisms. In response to anti-angiogenic treatment, tumors often
develop evasive resistance to the anti-VEGF agent used, switching from reliance on the
VEGF pathway to alternative pro-angiogenic signals, such as FGF, PDGF, or
angiopoietins. Secondly, hypoxia induced by the anti-angiogenic agents not only
upregulates pro-angiogenic signals, but also induces the recruitment of various bone
marrow derived cells such as vascular progenitors and vascular modulatory cells, which
can independently contribute to the tumor vasculature. Thirdly, anti-angiogenic therapy
in the absence of other chemotherapeutic agents will promote vessel normalization by
increasing pericyte coverage. This increases oxygen and nutrient delivery to the tumor
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despite lowering microvessel density. Lastly, tumors by their nature are highly adaptive.
With the loss of de novo vessel growth, cancers cells that are more invasive have a
survival advantage, resulting in increased local invasion and distant metastasis. For
example, in response to regression of the anti-VEGF-sensitive tumor vessels, gliomal
cells have been shown to co-opt normal vessels that are insensitive to anti-VEGF therapy,
and track along those conduits to invade locally (Bergers & Hanahan 2008). The failure
of the initial trials using anti-angiogenic therapy highlights the complexity of tumor
angiogenesis, and targeting it successfully requires further understanding of the interplay
between tumor cells and their microenvironment.

Calcineurin and Angiogenesis

Calcineurin biology
Calcineurin is a calcium regulated ser/thr phosphatase conserved from yeast to
humans (Krinks 1979). It is a ubiquitous signaling pathway downstream of many
extracellular signals with tissue-specific functions (Rusnak & Mertz 2000). Discovered as
a binding partner to the immunosuppressant cyclosporin A (CsA), the calcineurin
pathway (Liu et al. 1991) (Fig. 1.2.) was first delineated in T cells (Ho et al. 1996;
Clipstone & Crabtree 1992), and was later found to have important roles in neuronal
survival, myocardiocyte response to stress, vascular patterning, and angiogenesis
(Crabtree & Olson 2002). In response to an activating signal, such as T cell receptor
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(TCR) activation, there is an increase in intracellular calcium that binds to the calcium
modulated protein, calmodulin, which in turn activates the calcineurin complex.

Fig. 1.2. Overview of calcineurin signaling in endothelial cells.
Calcineurin is composed of the catalytic subunit calcineurin A and the regulatory
subunit B. In absence of calcium and calmodulin binding, calcineurin A is kept inactive
with an auto-inhibitory loop. When calmodulin is bound to calcium, it binds to
calcineurin B, which moves the auto-inhibitory loop out of position, allowing calcineurin
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to be enzymatically active. When active, calcineurin dephosphorylates its downstream
substrates, the most notable being the nuclear factor of activated T-cells (NFAT) family
of transcription factors (NFAT1-5) (Table 1.3), although a number of other calcineurin
substrates have also been identified. After dephosphorylation by calcineurin, NFAT
shuttles from the cytosol into the nucleus, where it acts as a transcription factor. (Rusnak
& Mertz 2000; Jain et al. 1993)
Table 1.3 NFAT family members.
Name
Alternate Expression Pattern
names
NFAT1 NFATc2
Immune cells, olfactory
NFATp
cells, endothelial cells,
skeletal muscle,
chondrocytes, adipocytes

NFAT2

NFATc1
NFATc

Immune cells, endothelial
cells, skeletal muscle

NFAT3

NFATc4

NFAT4

NFATc3
NFATx

NFAT5

TonEBP
OREBP

Embryonic: vascular
precursor
Endothelial cells,
adipocytes
Embryonic: vascular
precursor
Immune cells, endothelial
cells, skeletal muscle,
keratinocytes
Immune and tumor cells

Knockout phenotype
Immune hyperactivation and
allergic responses
Suppression of chondrogenesis
(NFAT1+2 double knockout =
failure of T cell activation and
immune response)
Lethal failure of cardiac
morphogenesis
Defects in thymic development
and T cell activation in RAG1-/chimeras
No apparent defects
(NFAT3+4 double knockout =
lethal vascular patterning
defects)
Defects in thymic development
and hyperproliferation of
lymphocytes

Unknown

In T-cells, nuclear NFAT transactivates genes that are required for T-cell activity,
such as IL-2 and the IL-2 receptor (Hogan et al. 2003). In other cell types, NFAT is
responsible for cell-specific gene transactivation or repression. For example, calcineurin
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is highly expressed in neuronal tissue and plays a role in neuronal plasticity and memory
consolidation (Mansuy 2003). The role of calcineurin in the vasculature is an active and
important area of research (Nilsson et al. 2008). Calcium signaling is highly regulated in
the myocardium. In embryonic cardiovascular development, calcineurin signaling is
involved in the migration of the myocardial precursors and the formation of the heart
valves (Chang et al. 2004). Post-natally, the calcineurin-NFAT pathway appears to
dichotomously regulate heart size and hypertrophic responses as well as exert a protective
effect on the heart (Molkentin 2004). Specific loss of calcineurin in the heart results in
mice with smaller hearts at baseline that are also refractory to hypertrophic growth (Frey
& Olson 2003). This and other studies indicate the potential for targeting calcineurin
signaling for developing therapies for hypertrophic cardiomyopathy (Frey & Olson 2003).

Calcineurin signaling in tumorigenesis
As the calcineurin-NFAT pathway regulates a variety of physiological tissuespecific cellular effects, it similarly has been found to be dysregulated in cancers with a
multitude of effects. There are five NFAT family members with varying degrees of
redundancy and specificity in their downstream effects (Table 1.3). NFAT1 and 2 have
similar DNA binding domains and are mostly functionally redundant. NFAT3 and 4 also
share similar roles (Crabtree & Olson 2002). Unlike other NFAT proteins, NFAT 5, is
not regulated by calcineurin (Mancini & Toker 2009). Dysregulation of NFAT expression
or signaling has been found in various cancers and reflects its tissue-specific functions.
Consistent with its role in the immune system, activated nuclear NFAT2 has been found
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in cases of hematological malignancies such as Burkitts lymphoma, diffuse large cell B
cell lymphoma, and T cell lymphomas, and responds to calcineurin inhibition (Mancini &
Toker 2009). Additionally, NFAT2 has been found to be overexpressed in pancreatic
cancers. Expression of NFAT1 in breast cancer promotes invasion and migration through
increased transactivation of the direct NFAT target, COX-2. Furthermore, the
calcineurin-independent NFAT5 has also been shown to be an effector in integrin
mediated migration but not invasion in breast cancer, demonstrating multiple and
complex roles of NFAT family members in tumorigenesis (Jauliac et al. 2002).

Calcineurin signaling in tumor angiogenesis
The calcineurin pathway in the tumor microenvironment plays a critical role in
tumor angiogenesis. Calcineurin is highly expressed in endothelial cells and is
downstream of VEGF signaling. Activation of VEGFR2 by its ligands increases
intracellular calcium, which activates calcineurin and subsequently causes NFAT nuclear
localization. In endothelial cells, NFAT promotes the transcription of angiogenesis
responsive genes, such as cyclooxygenase-2 (COX-2), E-selection, and tissue factor
(Hesser et al. 2004). The physiological relevance of the calcineurin-NFAT pathway in
tumor angiogenesis is illustrated in the Down Syndrome (trisomy 21) population.
Individuals with Down Syndrome have an extra copy of chromosome 21 and are
protected from up to 90% of solid tumors when compared to age-matched controls (Yang
et al. 2002), suggesting the increased expression of tumor suppressor genes. Alternatively,
as solid tumors require angiogenesis for progression, overexpression of anti-angiogenic
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regulators can tip the angiogenic balance against the growth of tumor vessel, halting solid
tumor growth. Indeed, chromosome 21 encodes DSCR-1, dual specificity tyrosinephosphorylation-regulated kinase 1A (DYRK-1A), and PCP-4, which are three negative
regulators of calcineurin. A mouse model of Down Syndrome also demonstrated
decreased tumor growth in a transplantable tumor model (Baek et al. 2009). Modest
overexpression of just one gene that negatively regulate calcineurin, DSCR-1, from three
alleles as opposed to two, was sufficient to inhibit calcineurin activity in endothelial cells,
resulting in decreased tumor growth and tumor angiogenesis. In light of this work, it is
clear the calcineurin pathway is a critical determinant in tumor angiogenesis and
inhibition by the endogenous protein DSCR1 can be potentially exploited to develop new
anti-angiogenic therapies for solid cancers. Furthermore, studies of trisomy 21 highlight
additional molecules such as DYRK-1A and PCP-4, also involved in the negative
regulation of calcineurin signaling, that may yield potential anti-angiogenic therapies.

Cyclosporin A and Tumorigenesis
Pharmacological calcineurin inhibitors have been used clinically for decades as
immunosuppressive drugs. Cyclosporin A (CsA), a cyclic fungal peptide, was first
identified in 1970s as a potent T cell inhibitor, and subsequently the entire calcineurinNFAT pathway was elucidated based on its interactions (Rusnak & Mertz 2000;
Clipstone & Crabtree 1992; Jain et al. 1993). As a potent immunosuppressant, CsA is
used primarily in organ transplant patients to prevent graft rejection, but is also used for
dermatological, ocular, and various autoimmune conditions. Within a cell, CsA
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complexes with intracellular cyclophilins, a family of peptidy-propyl isomerases (PPI).
When CsA is bound to the cyclophilin family member cyclophilin A, it forms a complex
that sits at the substrate docking site of calcineurin, acting as a competitive inhibitor
(Rusnak & Mertz 2000; Huai et al. 2002). Binding of CsA to other cyclophilins does not
affect calcineurin activity, but is responsible for calcineurin-independent effects of CsA.
Based on the positive role of calcineurin signaling in tumor angiogenesis, it would
be reasonable to assume that use of CsA, a calcineurin inhibitor, would decrease solid
tumor incidence. In contrast, there is a significant increase in the incidence of solid
tumors in the organ transplant population who are on long-term CsA therapy when
compared to aged matched controls. This increase in cancer risk is selective, with an
increase in virally associated lymphomas and leukemia, and more prominently, skin
cancers. Depending on the study, CsA therapy increases the risk of developing squamous
cell carcinomas by 65-250 times compared to the general population, followed by basal
cell carcinomas and melanomas (Kauffman et al. 2006). While non-transplant associated
squamous cell carcinomas and basal cell carcinomas can be fatal if left untreated, they
generally present as a slow growing tumors that are amenable to surgical excision and
have a good prognosis. CsA-associated skin cancers, however, are more locally invasive,
with much greater metastatic potential and a poorer prognosis (Dantal et al. 1998; Dantal
& Soulillou 2005).
This increase in cancer incidence after long-term CsA therapy is at odds with its
role as a calcineurin inhibitor. Since CsA is a potent immunosuppressant, it was assumed
that the increased cancer risk with CsA treatment was due to loss of immunosurveillance.
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However, loss of immunosurveillance is not sufficient to account for the significant
increase in tumorigenesis. Rapamycin, also an effective immunosuppressant used for
organ transplants, is not associated with increased cancer risk, and actually has been
shown to decrease tumor growth in some models (Guba et al. 2002). Additionally, CsA
treatment has been shown to promote tumorigenesis in an immune-independent manner.
In athymic nude mice and SCID mice, which lack functional B and T cells, CsA
treatment still promotes the growth of subcutaneous xenograft tumors (Hojo et al. 1999).
Several studies have investigated the mechanisms of CsA-associated tumorigenesis and
are discussed in the following sections.

CsA treatment and immunosuppression
Cancers are often referred to as “wounds that never heal,” and the inflammatory
contribution of immune cells to tumorigenesis is appreciated as a major regulator of
tumor progression (Dunn et al. 2002), both in promoting and inhibiting cancer
progression. The theory of immunosurveillance, first elaborated by Burnet and Thomas in
1957 (Burnet 1957; Burnet 1970), depicts the immune system as anti-carcinogenic,
recognizing cancer cells as “non-self” to be destroyed. Cancer cells, by their very nature,
have escaped the normal constraints of their role in a multi-cellular organism, and are
genetically and phenotypically different from normal cells. These differences allow for
immunological recognition, which preludes their destruction by the adaptive immune
system (Dunn et al. 2004). Additionally, infections by specific viruses such as human
papilloma viruses, hepatitis B and C viruses, and herpes viruses, can elevate the risk of
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associated cancer, especially if the infection is chronic and unresolved (Moore & Chang
2010). Loss of immunosurveillance, as in the context of acquired immunodeficiency
syndrome (AIDS) and various congenital defects, also elevates the risk of cancers (Gatti
& Good 1971; Simard et al. 2011). Since calcineurin is important for T-cell activation,
systemic CsA therapy results in profound immunosuppression. While CsA treatment in
immunodeficient mice has been shown to promote tumorigenesis (Hojo et al. 1999), it
does not absolutely exclude the contribution of CsA-induced immunosuppression to
tumorigenesis. The importance of immunosuppression in CsA and cancer risk is
highlighted by the elevated risk of virally-associated lymphoproliferative disorders
(Dantal & Soulillou 2005) in transplant patients. Furthermore, viral load of human
papilloma virus (HPV), which is associated with skin cancer risk, has been found to be
elevated in individuals on CsA therapy (Harwood et al. 2000). The causative contribution
of HPV to CsA-associated skin cancers, as it stands, is currently only correlative. The
high association of HPV presence with CsA-associated cancers may be a direct causeand-effect, or two separate and unrelated manifestations of CsA treatment. More studies
are required to elucidate the relationship between HPV infection, immunosuppression,
and CsA-associated cancers.

CsA treatment and TGF-β
One of the hallmarks of CsA-associated cancers is the markedly increased
invasiveness and high metastatic potential of these normally indolent tumor subtypes.
The first study investigating the tumorigenic effects of CsA explored its role as a
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metastatic promoter. CsA treatment in a transformed tumorigenic cell line induced an
invasive phenotype in vitro and increased metastasis in vivo. This was associated with
increased TGF-β production from tumor cells. TGF-β has a double-edged effect on
tumorigenesis; it suppresses cell proliferation and promotes differentiation, potentially
halting tumor initiation, but it also promotes epithelial-to-mesenchymal
transdifferentiation (EMT), which increases tumor invasion and cancer spread. Therefore,
TGF-β acts as a tumor suppressor early on in tumor progression and a tumor promoter at
later stages. In transformed malignant cells, CsA-induced TGF-β signals in a paracrine or
autocrine manner to increase migration and invasion. CsA-induced TGF-β was also
responsible for increased tumor metastasis in vivo, which was reduced to baseline with
TGF-β neutralizing antibodies (Hojo et al. 1999). In a xenograft squamous cell carcinoma
model, CsA-induced TGF-β caused EMT in tumor cells, marked by decreased E-cadherin
and increased N-cadherin, vimentin, snail, twist, fibronectin, and α-SMA (Walsh et al.
2011). In addition to promoting metastasis in mouse models of cancer, CsA-induced
TGF-β contributes to nephrotoxicity and gingival hyperplasia, also side effects of CsA
therapy (Naesens et al. 2009; Chung & Fu 2013). While TGF-β signaling can regulate
NFAT activity, it is not entirely clear whether CsA induces TGF-β through calcineurinNFAT inhibition or by a calcineurin-independent mechanism.

CsA treatment and cell proliferation
In addition to promoting metastasis, CsA has also been shown to increase cell
proliferation through Ras activation in renal carcinoma cells in vitro. By inhibiting
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carabin, a negative regulator of Ras, CsA treatment results in greater Ras activity,
offering an explanation for the rapid tumor growth seen in CsA-associated tumors (Datta
et al. 2009). CsA has also been shown to increase cell proliferation in non-transformed
cells. Gingival hyperplasia resulting from CsA treatment is thought to be due to a
combination of TGF-β production and fibroblast proliferation (Chung & Fu 2013).
Additionally, CsA-induced nephrotoxicity is at least partially attributed to glomerular cell
proliferation (O’Connell et al. 2012). There is little consensus in the literature on the
mechanism by which CsA promotes cellular proliferation. Several studies in nontransformed cells have demonstrated CsA can affect cell proliferation through a reactive
oxygen species (ROS) mediated hepatocyte growth factor pathway (O’Connell et al. 2012)
or through AKT activation (Han et al. 2010). It is therefore most appropriate to conclude
that CsA’s effect on cell cycle is complex and likely affecting multiple pathways in a cell
and context dependent manner.

DNA damage
UV rays are electromagnetic radiation with wavelength between 100-400nm and
is invisible to the naked eye but is emitted from many sources, with solar UV
representing the bulk of exposure to humans. UVA is a longer wavelength UV radiation
that can penetrate deep into the skin, but does not cause severe cellular damage, although
prolonged exposure results in photoaging. UVB, on the other hand, is a shorter
wavelength UV that can penetrate into the upper dermal layers, and has sufficient energy
to cause cellular damage, resulting in sunburns (Novarina et al. 2011). DNA will absorb
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UVB energy, which causes adjacent thymidine bases to bond together into pyrimidine
dimers. Left unrepaired, pyrimidine dimers will block transcription and replication,
stalling RNA and DNA polymerases, and can lead to double-stranded DNA breaks.
Pyrimidine dimers are repaired by the nucleotide excision repair (NER) pathway, a
conserved DNA repair pathway which specifically addresses UV-induced DNA damage.
Defects in the NER pathway lead to several diseases that predispose individuals to cancer
and early aging (Novarina et al. 2011).
Because CsA-associated tumors are predominately skin cancers, it had been
suggested that CsA may also negatively affect the NER pathway. The first support for
this hypothesis was seen in lymphocytes, where CsA treatment allowed UV irradiated
cells to re-enter the cell cycle without removal of the DNA damage product (Kuschal et
al. 2009; Ahlers et al. 1999). Further work in fibroblasts demonstrated that CsA
downregulates two of the proteins involved in NER, XP-A and XP-G, and this effect was
phenocopied by calcineurin knockdown (Kuschal et al. 2011). Lastly, CsA treatment
potentiated the carcinogenic effect of UV as shown by an increased incidence of skin
tumors in UV-irradiated mice on CsA therapy (Han et al. 2012). Taken together, these
studies convincingly show that CsA is involved in skin tumor initiation in the setting of
UV irradiation by amplifying the mutational potential of UV-induced DNA damage.

Inhibition of apoptosis by CsA
The inhibitory effect of CsA on calcineurin is mediated through its interaction
with cyclophilin A, but CsA can also bind to other cyclophilin family members, resulting
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in calcineurin-independent effects. The cellular functions of most cyclophilin proteins are
poorly characterized, making it difficult to determine the calcineurin-independent
outcomes of cyclophilin-cyclosporin interactions. The function of one cyclophilin protein,
cyclophilin D, however, is very well characterized, as is its binding with CsA. This
particular cyclophilin family member is localized to the mitochondria inner membrane
and is a regulatory component of the mitochondrial permeability transition pore (MPTP)
(Fig. 1.3.).
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BCL-2 family

outer
membrane
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space
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Fig 1.3. Current model of the mitochondrial permeability transition pore
(MPTP). Adapted from (Halestrap & Richardson 2014). The definitive structural
identity of the MPTP is under investigation, but the latest proposed model consists of
an outer pore formed by the voltage-dependent anion channel (VDAC), various
members of the BCL-2 family, and hexokinase (HK). The inner pore consists of
adenine nucleotide transporter (ANT), phosphate carrier (PiC), the c-subunit of the
FoF1-ATP synthase, and cyclophilin D (CypD). Creatine kinase (CK) bridge the
outer and inner pore. Other molecules such as translocator protein and protein kinase
C may also be associated (not shown).
The MPTP is a calcium and ROS responsive nonselective channel that, when
open, releases mitochondrial contents into the cytosol. Opening of the MPTP propagates
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the apoptotic cascade and also aids the removal of aged mitochondria. Cyclophilin D
regulates the stimulus threshold required for MPTP opening (Halestrap 2009).
Binding of CsA to cyclophilin D raises the stimulus threshold required for pore
opening, thereby decreasing pore opening. During conditions that trigger cell death
pathways, CsA decreases apoptosis by preventing mitochondrial content efflux. This
calcineurin-independent effect of CsA on the mitochondria has been confirmed through
studies with the non-immunosuppressive cyclosporin analog, NIM811, which
preferentially binds to cyclophilin D (Waldmeier et al. 2002). The anti-apoptotic effect of
CsA is consistent across cell types, and it is currently being investigated as a potential
therapeutic agent to attenuate ischemia-reperfusion injury in cardiac tissue (Piot et al.
2008). Considering evasion of apoptosis is a significant factor in tumorigenesis, the
ability of CsA to raise the apoptotic threshold allows for precancerous cells that would
otherwise be eliminated through cell death to survive.
This carcinogenic effect of CsA has been demonstrated in keratinocytes, the cells
of origin for epidermal squamous cell carcinomas, where CsA treatment decreased UVinduced apoptosis in vitro. This was found to occur in a calcineurin-independent manner
as only CsA and NIM811, but not FK506, an unrelated calcineurin inhibitor, decreased
UV-induced apoptosis (Norman et al. 2010). CsA-mediated evasion of apoptosis after
UV irradiation may potentiate skin cancer initiation, as CsA-associated cancers generally
occur in sun exposed areas and in individuals with low skin pigmentation (Moosa &
Gralla 2005).
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ATF3
Oncogenic Ras mutations, specifically H-ras, are found in 10-20% of skin cancers
(Boukamp 2005). Additionally, hyperactive Ras (beyond physiological levels), through
DNA damage response secondary to hyperproliferation, can induce irreversible cell cycle
arrest and senescence (Di Micco et al. 2006). Defects in oncogene-induced senescence
allows for propagation of cancer cells into an expanding tumor. Using H-ras transformed
human keratinocytes xenografted into immunocompromised mice; a recent paper showed
calcineurin expression is required for oncogene-induced senescence. Calcineurin
knockdown by siRNA or inhibition by CsA or FK506 bypassed oncogene-induced
senescence and resulted in large and poorly differentiated tumors. This previously
undescribed calcineurin-mediated oncogene-induced senescence was found to occur
through NFAT transrepression of activating transcription factor 3 (ATF3). ATF3 is a
stress-induced transcription factor found to both positively and negatively regulate the
cell cycle (Boyd & Yan 2006; Thompson et al. 2010), and in this study ATF3 was found
to function as a negative regulator of p53. Loss of calcineurin, or suppression by CsA,
removed this inhibition on ATF3 transcription, whose expression decreased p53 levels
bypassing Ras-induced p53-mediated senescence (Wu et al. 2010). The significance of
oncogene-induced senescence in cutaneous squamous cell carcinoma, however, is
controversial as it has only been described in vitro, but not in in vivo murine models
(Tarutani et al. 2003; Dajee et al. 2002). Therefore, while CsA and calcineurin are shown
to regulate ATF3 and senescence in mice, future studies are required to determine its
contribution to CsA-associated cancers in humans.
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CHAPTER 2: CYCLOSPORIN A PROMOTES TUMOR
ANGIOGENESIS AND ENDOTHELIAL CELL ACTIVATION IN A
CALCINEURIN INDEPENDENT MANNER

Introduction
Cyclosporin A (CsA) has been commonly prescribed for post-organ transplant
immunosuppression since 1983. A well-documented adverse event for patients on CsA
containing immunosuppressive regimens is a vastly increased risk of malignancy (Dantal
& Soulillou 2005; Euvrard et al. 2003). With improvements in the organ-transplant field
over the last few decades, allograft recipients are living longer, and CsA-associated
tumorigenesis is an important cause of morbidity and mortality in that population. Newer
generation immunosuppressants such as rapamycin and FK506 are replacing CsA as
transplant immunosuppressants due to decreased side effects such as renal toxicity and
malignancy risk. Many transplant recipients, however, have had past exposure to CsA
prior to medication adjustment or are still on CsA therapies due to prescriber preference.
Delineating the mechanisms by which CsA promotes tumorigenesis is critical for
management and prevention of this adverse drug effect and may provide a greater insight
on the role of the calcineurin pathway in cancer.
It has long been assumed that CsA increases cancer risk through its
immunosuppressive effects, leading to the loss of immunosurveillance, and escape of
transformed tumor cells from immunoediting (Dunn et al. 2002). This hypothesis is
supported by the fact that virally induced leukemias and lymphomas are found among
CsA-associated malignancies (Durnian et al. 2007). However, the use of other equally
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effective immunosuppressants for organ transplant patients, such as FK506 or rapamycin,
is not associated with a similar cancer risk (Kauffman et al. 2006). Additionally, CsA
treatment of immunocompromised mice promotes tumor growth and progression (Hojo et
al. 1999), suggesting that at least one mechanism of CsA-induced tumorigenesis is
independent of immunosuppression.
There are several known pathways through which CsA can promote
tumorigenesis discussed in detail in Chapter 1 and summarized in Figure 2.1. With the
exception of increasing the apoptotic threshold, the effects of CsA on tumorigenesis have
been shown or assumed to occur through calcineurin inhibition. Calcineurin
dysregulation has been found in cancer cells as well as in the tumor microenvironment.
The role for the calcineurin pathway in mediating tumor angiogenesis has been well
characterized (Baek et al. 2009; Yao & Duh 2004; Nilsson et al. 2008). The calcineurinNFAT pathway is downstream of VEGF receptor activation in endothelial cells and
transactivates angiogenesis-responsive genes. Suppression of calcineurin activity by its
endogenous inhibitor Down syndrome candidate region 1 (DSCR1) results in a
significant decrease in tumor growth due to inhibition of tumor angiogenesis (Baek et al.
2009; Hesser et al. 2004; Chan et al. 2005; Yao & Duh 2004; Iizuka et al. 2004),
suggesting a potential role for calcineurin inhibitors as anti-angiogenic therapy. As a
pharmacological calcineurin inhibitor, the pro-tumorigenic effect of CsA is inconsistent
with the established role for calcineurin in tumorigenesis. Studies examining the ability
of CsA to negatively regulate tumor angiogenesis in a manner similar to DSCR1 are
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limited. We therefore sought to examine the potential effects of CsA on tumor
vasculature.

Figure 2.1. Overview of the known mechanisms of cyclosporin A on
tumorigenesis. The pathway or factors directly affected by CsA are highlighted in
yellow. Abbreviations: MPTP = mitochondrial permeability transition pore, NER =
nucleotide excision repair, ATF3 = activating transcription factor 3, TGF-β
=transformation growth factor β

FK506, or tacrolimus, is another calcineurin inhibitor also used in post-organ
transplant immunosuppression. Patients on FK506-containing immunosuppressive
regimens experience significantly decreased rates of malignancy compared to patients on
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CsA (Kauffman et al. 2006), suggesting CsA’s ability to promote tumorigenesis, at least
in part, is calcineurin-independent.
While CsA forms a calcineurin-inhibitory complex with the cyclophilin family
member cyclophilin A (CypA), it may also bind to other intracellular cyclophilins and
mediate calcineurin-independent effects. For example, when bound to cyclophilin D, CsA
increases the apoptotic threshold (Halestrap 2009). Therefore, we wanted to investigate
the role of CsA in the tumor microenvironment and determine whether these effects
depend on calcineurin.
Based on previous reports showing that CsA treatment promotes tumor
angiogenesis in a colon cancer model (Guba et al. 2002), we expect that chronic CsA
treatment will also increase tumor angiogenesis in a skin cancer model. In order to
evaluate the effect of CsA on angiogenesis, we characterized the effect of CsA on solid
tumor growth and angiogenesis in vivo and on endothelial cell proliferation and migration
in vitro. To assess for the calcineurin-dependence of these effects of CsA on angiogenesis,
we utilized endothelial cells with a genetic deletion of calcineurin as well as cyclosporin
analogs and other small molecule calcineurin inhibitors.
We show that chronic CsA treatment increases tumor growth in two separate
mouse models of skin cancer with increased tumor microvessel density. Treatment of
primary mouse endothelial cells in vitro with CsA results in increased proliferation and
migration. CsA-induced endothelial cell activation is calcineurin-independent, as it still
occurs following genetic deletion of calcineurin and is not seen following treatment with
other calcineurin inhibitors.
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Results

Cyclosporin A treatment increases skin tumorigenesis in vivo
Previous studies investigating the in vivo effect of CsA on tumor growth were
conducted in diverse tumor types including renal and lung carcinoma models. However,
patients on long-term CsA treatment predominantly have an elevated risk of skin cancers.
Therefore, to study the effect of CsA on tumor angiogenesis in a cancer type most
relevant to the patient population on CsA therapy, we examined these effects in a
chemically induced mouse model of skin cancer and in mice allografted with murine
melanoma cells.
To model squamous cell carcinoma, we used a well-characterized two-step
chemical carcinogenesis model (Abel et al. 2011; Verma & Boutwell 1980) that results in
de novo skin cancers. This model involves the one time topical application of the tumor
initiator 7,12-dimethylbenz[α]anthracene (DMBA), which causes DNA damage and the
emergence of H-ras mutant keratinocytes in the epidermis, followed by twice weekly
application of the tumor promoter 12-O-Tetradecanoylphorbol-13-acetate (TPA). With
continual carcinogen treatments, oncogenic mutations accumulate in keratinocytes,
resulting in premalignant papilloma growth (Fig. 2.2.A). These papillomas are benign,
but have pathological features similar to squamous cell carcinoma, such as the expansion
of the basal cell layer, nests of tumor cells, and keratin pearls. Over time, they may
progress into invasive carcinomas, although this is dependent on the genetic background
of the mouse (Kemp et al. 1993). In the mouse strain used here (C57/BL6), 40 weeks of
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TPA treatment did not result in carcinoma conversion. However, chronic CsA treatment
of these mice at the clinical dose of 10mg/kg five days a week resulted in a significant
increase in the number of dermal papillomas (Fig 2.2.B). The number of large papillomas
was also greater, although not significantly so, in CsA treated mice (Fig 2.2.C).
Because CsA also increases the incidence and progression of melanomas in organ

Figure 2.2. Cyclosporin A (CsA) treatment increases skin tumorigenesis in vivo.
(A) Hematoxylin and eosin staining of WT C57/BL6 mouse skin. The left image is of
normal skin. The middle and right images are of DMBA-TPA induced skin
papillomas 40 weeks after treatment initiation with arrows pointing to expansion of
the basal cell layer and keratin pearls, respectively. Quantification of (B) total
papilloma per mouse or (C) only large papillomas in mice treated daily with peanut
oil (vehicle) or 10mg/kg CsA. Representative photos are shown on the right (B) with
papilloma highlighted in red. N=5 per group. (D) Tumor growth over time of
subcutaneous xenograft tumors in mice treated with vehicle or CsA. WT mice were
pre-treated with CsA or vehicle for 14 days prior to tumor inoculation and maintained
on drug for duration of study. Results are representative of three experiments, with
n=3-5 per group. Error bars indicate SEM, and * P <0.05 for all experiments.
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transplant patients (Euvrard et al. 2003), we investigated the tumorigenic effects of CsA
on melanoma in the B16-F10 transplantable melanoma mouse model. Chronic CsA
treatment in wild type mice with allografted B16-F10 melanoma cells increased tumor
growth compared to untreated mice (Fig 2.2.D). These data show that CsA treatment in
mice potentiates skin tumorigenicity in at least two in vivo models of skin cancer.

Cyclosporin A increases tumor angiogenesis
Expansion of solid tumors is in part limited by the growth of new blood vessels in
the tumor. Since calcineurin inhibition by DSCR1 suppresses neoplastic angiogenesis, we
wanted to study the effect of CsA in the tumor microenvironment. Its function as a
calcineurin inhibitor should block VEGF signaling in endothelial cells, decreasing tumor
angiogenesis. The increase in tumor growth seen with CsA treatment, however, is
inconsistent with that hypothesis.
Chemically induced dermal papillomas from mice treated with CsA or vehicle
control were harvested and sectioned for histopathological analysis. Vessel-like structures,
characterized by a conspicuous lumen lined with end-to-end elongated cells that feature
flat thin nuclei, are easily distinguishable (Fig 2.3.A), and their distribution in the tumor
is heterogeneous. Analysis based on the number of vessels per tumor shows a trend
towards more total vessels per mouse (Fig. 2.3.B), but no difference in vessel number per
tumor if tumor size is taken into consideration (Fig 2.3.C & D). In our hands,
immunofluorescence of tumor sections with anti-CD31 and anti-VE-Cadherin antibodies,
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specific markers of endothelial cells was unsuccessful due to a high degree of
autofluorescence in the skin tissue.
A major limitation of the DMBA-TPA carcinogenesis model is that while it
accurately portrays skin tumor progression, the tumors generated have heterogeneous
vessel distribution that is difficult to quantify. Differences between treatment groups may
be obscured by the varied structure of this particular tumor tissue. Additionally,
papillomas on the C57/BL6 genetic background, which is relatively resistant to
carcinoma conversion, do not grow very large and may not provide sufficient hypoxic
stimulus for angiogenesis.

Figure 2.3. CsA treatment on tumor angiogenesis in the DMBA-TPA induced
skin cancer model. (A) Representative H&E staining of DMBA-TPA induced skin
papilloma. Black triangles indicate putative endothelial cells lining tumor vessels, and
scale bars indicate 50µm. (B) Quantification of total vessels counted per mouse in
each cohort, each dot represents a mouse. (C) Quantification of total vessels counted
per tumor in each cohort, each dot represents a tumor. (D) Quantification of vessels
stratified by tumor size in each cohort.
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B16-F10 allograft melanoma tumors also demonstrated increased tumor growth
when treated with CsA, so we also assessed the role of CsA in tumor angiogenesis in this
model. Melanoma allograft tumors were harvested from mice maintained on CsA or
vehicle therapy and frozen sections were immunostained with anti-CD31 antibody and
Hoechst. Random low powered images of the tumors were taken (Fig. 2.4.A) and CD31
positive units, vessel number, lumenized vessels, and large vessels (≥100µm) were
counted and analyzed. We found an increase in CD31 positive units and total vessel
number in tumors from mice that were treated with CsA (Fig. 2.4.B). There was no

Figure 2.4. CsA treatment increase tumor angiogenesis in the B16-F10 allograft
tumor model. (A) Representative immunofluorescence images of B16-F10 tumor
sections stained with anti-CD31 (red) and Hoechst (blue), scale bars indicate 100µm.
(B) Quantification of microvessel density, number and size. Microvessel density is
quantified by the total number of CD31+ units in a high powered field (hpf),
lumenized CD31+ structures and CD31+ structures measuring 100µm or longer are
also counted. (C) Quantification of Evans blue dye in tumor tissue normalized to
tumor weight. B16-F10 tumor-bearing mice were treated with either vehicle or CsA.
Error bars indicate SEM, and * P <0.05 for all experiments.
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significant change in the number of lumenized vessels, and only a small increase in the
number of large vessels (≥100µm) in tumors from mice treated with CsA compared to
vehicle (Fig. 2.4.B). The majority of the increased microvascular density found in CsAtreated tumors consisted of small, short CD31+ structures. These findings where CsA
treatment leads to an increase in small short vessels without affecting larger or lumenized
vessels suggests that CsA may promote the early stages of tumor angiogenesis, which is
marked by cell proliferation and sprout formation.
It remains undetermined whether CsA has an effect on vessel maturation and
leakiness. We sought to test the effect of CsA on tumor vessel permeability by injecting
Evans blue dye into the systemic circulation, then quantifying its tissue distribution.
There were no differences in tumor vessel permeability between groups (Fig. 2.4.C).
However, there was high variation in each group, potentially obscuring subtle differences.

Cyclosporin A treatment promotes endothelial cell activation in vitro
To isolate the specific effects of CsA on the process of angiogenesis, we treated
primary endothelial cells isolated from the lungs of adult mice with CsA. These
microvascular endothelial cells are isolated using anti-CD31-conjugated magnetic beads
and generally are 90-95% CD31+. CsA treatment of primary endothelial cells led to
increased cell number over time (Fig. 2.5.A) with increased 5-bromo-2’-deoxyuridine
(BrdU) incorporation (Fig. 2.5.B), a synthetic nucleotide whose incorporation into a cell
indicates active DNA replication. We also assessed for apoptosis using terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL), an apoptotic marker
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Figure 2.5. Cyclosporin A potentiates endothelial cell proliferation and
migration in vitro. (A) Cell numbers of endothelial cells with 0.25µM CsA or
vehicle treatment. Results are representative from three experiments, with n=3 per
group. (B) Representative images of endothelial cells treated with 0.25µM CsA,
5ng/mL EGF or vehicle for 48 hours, pulsed with BrdU (red), and stained with
Hoechst (blue). Quantification of BrdU+ cells is shown in the graph. (C)
Quantification of TUNEL+ endothelial cells after treatment with vehicle or CsA for
72 hours or doxorubicin (Dox) for 24 hours, n=5 per group. (D) Representative
images of endothelial cells migrating through a transwell filter with vehicle or
0.25µM CsA treatment. Quantification of cells counted per hpf is shown on the
bottom. FGF (100ng/ml) is used as a positive control. Results are representative of
three experiments. (E) WT endothelial cells were treated with vehicle or CsA and
then seeded onto Matrigel and images were taken 5.5 hours later. Error bars indicate
SEM, and * P <0.05 for all experiments. n.s. = not significant. Scale bars in (B), (D),
and (E) indicate 100µm.
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which labels fragmented DNA, and found no difference in TUNEL staining between
vehicle and CsA treated cells (Fig. 2.5.C). These data indicate that CsA increases
endothelial cell proliferation.
During the early stages of angiogenesis, endothelial cells migrate towards
chemotactic gradients to form the nascent vessel before coalescing together to form a
tube (Carmeliet 2000). To test the effect of CsA on endothelial cell migration, we pretreated endothelial cells with CsA for two hours and created a CsA gradient in the lower
well of the Boyden chamber. We found more cells migrated through the transwell filter
with CsA treatment (Fig. 2.5.D) after 4 hours. Lastly, we tested the effect of CsA on
endothelial cell tube formation, an in vitro measurement of endothelial cell adhesion,
migration, protease activity, and tubule formation. Endothelial cells were plated onto a
Matrigel matrix, and over the next 4-12 hours they invade and coalesce together to form
tube-like structures. CsA treatment had no effect on endothelial cell tube formation
compared to control treated cells (Fig. 2.5.E). These data suggest that CsA promotes
angiogenesis through proliferation and migration with little effect on adhesion and tube
formation.

Calcineurin inhibitors (CNI) have differential effects on endothelial cell activation
The calcineurin pathway is found downstream of VEGFR2 signaling in
endothelial cells, and its activity in these cells results in transactivation of pro-angiogenic
genes like E-selectin, COX-2, and tissue factor (Armesilla et al. 1999; Hernández et al.
2001). The endogenous calcineurin inhibitor DSCR-1 has been shown to inhibit
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endothelial cell proliferation (Baek et al. 2009; Hesser et al. 2004; Chan et al. 2005; Yao
& Duh 2004; Iizuka et al. 2004). It is therefore inconsistent that CsA, a potent calcineurin
inhibitor, increases endothelial cell proliferation and migration. As a small molecule
inhibitor, CsA may have additional effects independent of calcineurin inhibition.
To test whether the endothelial cell phenotype induced by CsA is due to
calcineurin inhibition, we compared the effects of CsA with those of two other
calcineurin inhibitors. First, we made use of transgenic Dscr1 mice which express three
alleles of the endogenous calcineurin inhibitor Dscr1, resulting in increased protein levels
(Baek et al. 2009). There were fewer DMBA-TPA induced papillomas in transgenic
Dscr1 mice compared to wild-type mice treated with CsA (Fig. 2.6.A). Additionally, CsA
treatment of DSCR1 overexpressing endothelial cells increased cell proliferation (Fig.
2.6.B) whereas DSCR1 overexpression by itself decreased cell numbers compared to
wild type cells (Baek et al. 2009), suggesting separate and distinct underlying
mechanisms by which these two calcineurin inhibitors act in endothelial cells. We also
assessed the effects of the structurally dissimilar but functionally comparable small
molecule inhibitor FK506, which is also used clinically as an immunosuppressant.
Whereas CsA binds to cyclophilin A to inhibit calcineurin, FK506 instead binds to FK
binding proteins and forms an independent but convergent calcineurin inhibitory complex.
FK506 treatment of B16-F10 allograft tumor-bearing mice resulted in smaller tumors
compared to CsA-treated B16-F10 allograft tumor-bearing mice (Fig. 2.6.C), consistent
with the hypothesis that CsA promotes tumorigenesis in a calcineurin-independent
manner. FK506 treatment decreased endothelial cell numbers and inhibited VEGF41

induced migration in vitro when compared to CsA (Fig. 2.6.D&E) The differential effects
seen with CsA and FK506 suggests these two molecules, despite both being calcineurin

Fig. 2.6. Calcineurin inhibitors have opposing effects on tumorigenesis and
endothelial cell activity. (A) Quantification of DMBA-TPA induced skin papilloma
measured over time in Dscr1 transgenic (Tg) or WT mice treated with vehicle or CsA.
(B) Proliferation of WT and Dscr1 Tg primary endothelial cells after treatment with
vehicle or 0.25µM CsA. Cell numbers are counted every other day. (C)
Quantification of B16-F10 melanoma tumor growth in WT mice in either control
group, treated with 10mg/kg CsA or 0.15mg/kg FK506, tumor size is shown on the
right. (D) Proliferation of WT primary endothelial cells after treatment with vehicle,
0.1µM FK506, or 0.25µM CsA. (E) Quantification of endothelial cells migrating
through a transwell filter in response to vehicle, 100ng/mL VEGF, and 0.1µM FK506
or 0.25µM CsA. Error bars indicate SEM, and * P <0.05 for all experiments.
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inhibitors, have separate effects. We expected that FK506, as a calcineurin inhibitor,
would decrease endothelial cell numbers but instead found it had no effect on cell
numbers when compared to the vehicle treated group. This result suggests a calcineurinindependent action of FK506 on FK binding proteins, which are highly expressed in
endothelial cells (Higgins et al. 2003) with poorly delineated functions, but its inhibition
by FK506 may independently affect angiogenesis. FK506 is known to be a more potent
calcineurin inhibitor than CsA (Woo & Propper 1990), and the concentration of FK506
used in vitro was adjusted to account for this discrepancy. A dose-curve, however, was
not performed and may further explain the differences. Taken together, these data are
highly suggestive of a pro-angiogenic effect of CsA that occurs independent of
calcineurin signaling.

Cyclosporin A treatment activates endothelial cells in a calcineurin-independent
manner.
To investigate the effects of CsA treatment in absence of calcineurin, a transgenic
mouse strain with a conditional calcineurin deletion was utilized. This transgenic mouse

Figure 2.7. Adenovirus Cre infection in Calcineurin Bf/f (CnBf/f) endothelial cells (EC)
results in the loss of calcineurin A protein. Western blot showing calcineurin A protein
in endothelial cells without Adeno-Cre infection, or with Adeno-Cre infection at the
indicated infection ratio and passage (P) number. Endothelial cells were infected at P1
and Calcineurin B deletion was assessed by presence of calcineurin A protein at P2 and
P6.
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has loxP sites flanking the calcineurin B (CnB) gene, which is excised upon Cre
recombinase administration. Without CnB, the catalytic calcineurin A subunit degrades.
Primary lung endothelial cells were isolated from CnBflox/flox mice and treated in vitro with
adenovirus carrying Cre recombinase (Adeno-Cre). Upon infection with Adeno-Cre,
calcineurin A protein is lost from endothelial cells within 1-2 passages and remains
absent for up to four additional passages in vitro (Fig. 2.7.).
In agreement with our earlier pharmacologic data, CsA treatment in
calcineurin-null endothelial cells increases cell numbers, comparable to its effect in wild
type endothelial cells (Fig. 2.8.A&B). Calcineurin deletion in endothelial cells results in a
near complete loss of migration through a transwell filter (Fig. 2.8.C&D). These data
demonstrate that calcineurin is not required for the pro-proliferative phenotype induced
by CsA in endothelial cells.
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Fig. 2.8. Calcineurin is not required for cyclosporin A-induced endothelial cell
proliferation and migration (A, B) Proliferation of uninfected (A) or adenovirusCre infected (B) Calcineurin Bflox/flox (CnBf/f) primary murine endothelial cells in the
presence of 0.25µM CsA or vehicle alone. Cell numbers were counted every other
day. (C, D) Representative images of uninfected (C) or adenovirus-Cre infected (D)
CnBf/f primary murine endothelial cells migrating through a transwell filter in
response to 0.25µM CsA or vehicle alone. FGF is used as a positive control.
Quantification of cells per high-powered field (hpf) is shown on the bottom. Scale
bars indicate 100µm. Results are representative of two experiments, with n=3 per
group. Error bars indicate SEM, and * P <0.05 for all experiments.
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Discussion

Our data show that chronic CsA treatment in vivo promotes skin tumorigenesis in
two separate murine skin cancer models. This is accompanied by increased tumor
angiogenesis with amplification in the number of short small vessels and minimal change
in the number of large lumenized vessels. In vitro, CsA increases the proliferation and
migration of primary endothelial cells. This occurs in a calcineurin-independent manner,
as calcineurin-null endothelial cells responds to CsA in a manner similar to wild-type
endothelial cells, and these effects were not seen with other calcineurin inhibitors.
Considering the cancer profile associated with CsA therapy in transplant
populations, it would be pertinent to use a skin cancer model to study this phenomenon in
mice. Since CsA-associated cancers skew significantly towards squamous cell
carcinomas (SCC), in vivo mouse models of SCC would be ideal for studying CsA’s
effect on tumorigenesis. There are several in vivo SCC progression mouse models; the
chemical carcinogenesis (DMBA-TPA) model described earlier in this chapter and UV
irradiation of hairless/shaved mice (Gruijl & Forbes 1995). Additionally, genetic
manipulation of p53 and Ras in the dermis, in combination with chemical carcinogens,
has also been shown to produce SCC (Caulin et al. 2007; Zhang et al. 2005). Lastly, SCC
xenografts, comprised of human SCC cell lines or H-ras overexpressing human
keratinocyte grafts (Wu et al. 2010) have also been used to study skin cancer progression.
Given the multi-stage nature of the DMBA-TPA skin carcinogenesis model and
its similarity to human disease (Abel et al. 2011; Verma & Boutwell 1980), it was a
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reasonable model to study the effects of CsA on cancer. CsA treatment in C57/Bl6 mice
subjected to multiple rounds of topical carcinogens had more papilloma growth than
vehicle treated mice. However, the genetic background of the mouse has a significant
impact on cancer progression. In the C57/Bl6 mouse strain in our studies, these
papillomas never converted to carcinomas nor grew very large, making it difficult to
assess the angiogenic requirements of the tumors. It is also unclear whether the increase
in papilloma number found in CsA-treated mice is due to increased angiogenesis or if it is
a direct effect of CsA on keratinocytes, as CsA has also been shown to suppress cell
death and DNA damage repair in DNA-damaged keratinocytes (Yarosh et al. 2005;
Norman et al. 2010; Han et al. 2012). Although the cytochrome P450 isozyme
responsible for converting DMBA from a prodrug to its more carcinogenic form DMBADE is distinct and separate from the P450 isozymes which metabolize CsA (Gao et al.
2005; Staatz et al. 2010), we cannot rule out a drug interaction between DMBA and CsA
through the induction of P450 enzymes. It is also interesting to note that in our
experiments, the number of papillomas per mouse increased steadily over time until week
20, then remained relatively stable for the duration of the experiment (20 additional
weeks) despite continued TPA administration, suggesting a limitation in papilloma
numbers imposed by the initial number of DMBA transformed cells. Moreover, the tumor
structure of the papillomas was heterogeneous, and randomly taken images showed high
variation in vessel-like structures, making vessel density highly variable and
quantification of angiogenesis difficult.

47

Subcutaneous xenograft injections of the human squamous cell carcinoma cell
line SCC-13 (Okano et al. 2000) resulted in high variability in tumor size within each
group (data not shown), potentially obscuring any treatment effects. Due to these
limitations, we were not able to assess the effect of CsA on angiogenesis in this in vivo
model of SCC.
While transplant patients on CsA therapy have an increased risk of squamous cell
carcinoma, they are also at elevated risk for basal cell carcinoma and melanoma. The
B16-F10 allograft mouse model of melanoma is a well-characterized model for studying
melanoma, angiogenesis, and metastasis (Ryeom et al. 2008; Nicolson et al. 1978).
Therefore, we utilized the transplantable B16-F10 melanoma cells in an allograft tumor
model to determine the effect of CsA on tumor angiogenesis. CsA treatment increased
tumor angiogenesis as well as tumor size, which was consistent with our hypothesis.
However, there are limitations to this model. The subcutaneous allograft injection of
already transformed B16-F10 tumor cells into the mice allows for studying tumorigenesis
only in the late progression stage, as tumor initiation and early progression is bypassed.
Additionally, while B16-F10 allograft tumor model have been used by other groups to
study metastasis, in our hands, this metastasis model showed high variability from
experiment to experiment and could not be used to assess the effects of CsA on
metastasis.
To best understand whether CsA has a pro or anti-angiogenic effect on
tumorigenesis, we used the clinically relevant dose of 10mg/kg CsA for our in vivo
experiments, a comparable dose used for transplant patients. We did not, however, assess
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the serum levels of CsA in the mice to compare to human populations. When used at this
dose, CsA therapy consistently increased the number and size of solid tumor formation
(Yajima et al. 2008; Guba et al. 2002) as well as tumor angiogenesis (Guba et al. 2002).
In the B16-F10 allograft melanoma mouse model, CsA treatment had a specific effect on
the quantity and phenotypic appearance of tumor vessels.
While neoplastic vessels are generally considered to be inferior conduits for
nutrient and oxygen delivery compared to normal vessels, they are still able to meet some
of the metabolic demands of the tumors. Although tumor vasculature varies depending on
the tumor type, the microvessel density in most solid tumors has been shown to be
correlated with greater tumor growth, decreased patient survival, and poorer prognosis
(Hlatky et al. 2002).
In the B16-F10 allograft melanoma model, the tumor vasculature consists of a
mixture of immature and mature vessels, including lumenized larger vessels. CsA
treatment increased the overall microvessel density of the tumors, which would raise the
metabolic limit on the tumor cells imposed by vessel density. Additionally, CsA
treatment resulted in a striking increase in small and short vessels, with little or modest
change in the number of lumenized vessels or larger vessels. In a hypoxic tumor,
increases in vessel density, even small and immature vessels, still aid in nutrient delivery.
Due to technical limitations, we were unable to determine the effects of these
additional small vessels on tumor and tissue perfusion. While we have shown by staining
that there are increased vessel structures within the tumors, in vivo labeling of tumors
with FITC-lectin or FITC-dextrin would be helpful to determine in vivo functional quality
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of these vessels. Alternatively, Doppler ultrasound could be used to assess fluid/blood
flow within the tumor, and tumor pO2 could be measured with an Eppendorf fine needle
probe (Menon et al. 2003). While the time frame of our tumor model did not allow for
metastasis, immature small vessels often show a paucity of pericytes and leakier cell to
cell junctions compared to mature vessels and could promote increased tumor cell escape
into the periphery. Future studies using metastatic cancer models could determine
whether the aberrant tumor vessels induced by CsA treatment contribute to the metastatic
potential of solid tumors.
Because CsA treatment likely affects multiple signaling pathways in endothelial
cells, we conducted our experiments using a low dose of CsA that fell within the proproliferative range in order to best dissect the pro-angiogenic effects of CsA. Using this
dose, we show that CsA-treated endothelial cells have greater proliferation and migration
in vitro compared to vehicle treated cells, but no difference in tube formation in Matrigel.
The tube formation assay is an in vitro model for the later stages of angiogenesis, such as
adhesion, matrix invasion, and capillary tube formation. However, due to the short time
frame and reduced growth factor conditions, endothelial cell tube formation does not
accurately reflect changes in proliferation. These data suggest that CsA specifically
affects the early stages of angiogenesis, especially endothelial cell proliferation and
migration. Future characterization of protease production and activation, as well as cell
surface receptors (adhesion molecules, VEGFR, Tie receptors) in endothelial cells would
be helpful to further elucidate the specific angiogenic pathways affected by CsA.
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Systemic CsA treatment results in drug accumulation in multiple tissues and cell
types in addition to tumor and endothelial cells. Pericytes or vascular smooth muscle cells
are important vascular regulators and are often abnormal in neoplastic vessels. While the
effect of CsA on tumor-associated vascular smooth muscle cells is not known, previous
studies have demonstrated that CsA can affect proliferation, adhesion, and cellular
orientation of vascular smooth muscle cells (Garvey et al. 2010). Our study demonstrates
a direct effect of CsA on endothelial cells in vitro but does not rule out the potential
involvement of other cell types such as vascular smooth muscle cells. Staining of tumors
from CsA-treated mice for vascular smooth muscle markers in combination with
permeability studies and in vitro characterization of vascular smooth muscle cells after
CsA treatment in co-culture experiments with endothelial cells or tumor cells may help
clarify the contribution of vascular smooth muscle cells to the CsA-associated
angiogenesis.
While we are studying the effect of CsA in the context of tumor angiogenesis, it
has been investigated by other groups in nonmalignant pathological angiogenic settings,
although the results are varied and appear to be dose-dependent. Generally, high doses
(>5µM) of CsA in vitro has been found to be anti-angiogenic. One study found that CsA,
in combination with the antifungal drug itraconazole, is selectively toxic to endothelial
cells (Nacev & Liu 2011). The same group found that CsA was toxic to human umbilical
vein endothelial cells in a calcineurin-independent manner, presumably through binding
to cyclophilins (Nacev et al. 2011). In a mouse model of neovascular (wet) macular
degeneration, both CsA and a non-immunosuppressive analog N-MeVal-4-CsA
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decreased choroidal neovascularization (Nacev et al. 2011). Low doses (<0.5-1µM) of
CsA, on the other hand, have been shown to exert a cytoprotective effect on endothelial
cells in vitro by increasing VEGFR2 levels (Alvarez-Arroyo 2002). If CsA has dosedependent cellular effects on endothelial cells, there must be a combination of
independent pathways affected, one of which is the inhibition of the angiogenic
calcineurin-NFAT axis. Therefore, in order to produce the pro-angiogenic effects
observed, CsA must evoke an alternative, activating pathway in endothelial cells.
Most studies involving CsA assume that the effects seen occur in a calcineurindependent fashion. In our experiments, the pro-proliferative effects induced by CsA in
endothelial cells are at odds with the known effects of calcineurin inhibition in this cell
type. Therefore, we hypothesized that these events occur in a calcineurin-independent
manner. In agreement with this, other CNIs have dissimilar effects on tumorigenesis and
endothelial cell activity when compared to CsA. It is important to note, however, that
calcineurin inhibition by DSCR1 and FK506 in in vivo murine tumor models is not
limited to endothelial cells but extends to other cell types. Therefore, we also assessed the
effect of different CNIs on endothelial cells in vitro. Additionally, while we used a lower
concentration of FK506 for in vitro studies to partially reflect its greater potency (Kino et
al. 1987), ideally a dose curve would be more informative.
We found that calcineurin loss in endothelial cells had no effect on the ability of
CsA to increase proliferation; therefore, we concluded that CsA promotes pro-angiogenic
behavior in endothelial cells in a calcineurin-independent manner. However, this does not
necessarily mean that calcineurin inhibition by CsA does not have a significant effect in
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endothelial cells, as it still occurs regardless of off-target effects and likely explains the
toxicity seen at high doses.
In summary, our data show that CsA increases tumor growth and angiogenesis in
vivo, and it promotes endothelial cell proliferation and migration in vitro in a calcineurin
independent manner. In chapter 3, we will explore potential calcineurin-independent
pathways stimulated by CsA treatment that may be responsible for the pro-proliferative
and migratory effects seen in endothelial cells.
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CHAPTER 3: CYCLOSPORIN A INCREASES ENDOTHELIAL
CELL ACTIVITY THROUGH MITOCHONDRIAL REACTIVE
OXYGEN SPECIES
Introduction

Our studies indicate that cyclosporin A (CsA) treatment increases tumor growth
and angiogenesis in a mouse model of skin cancer. CsA treatment of endothelial cells in
vitro increases proliferation and migration. These CsA-induced endothelial cell effects
occurred in a calcineurin-independent manner, as CsA still affects calcineurin-null cells
in a similar manner. Furthermore, treatment with other calcineurin inhibitors does not
recapitulate this phenotype. Therefore, we investigated the underlying mechanism of
CsA-induced endothelial cell activation in the absence of calcineurin.
CsA is a fungal cyclic decapeptide with a high affinity for a family of intracellular
poly-propyl-isomerases (PPI) called cyclophilins (Hemenway & Heitman 1999). This
family of sixteen proteins catalyzes the cis to trans isomerization reaction in folding
proteins. They act mostly as chaperone proteins and are implicated in both physiological
and pathological processes (Wang & Heitman 2005). CsA binds to the cyclophilin family
member cyclophilin A and forms a calcineurin-inhibitory complex, which occupies the
substrate docking site and competitively displaces calcineurin substrates such as NFAT
from docking and being dephosphorylated. The selectivity of this CsA-cyclophilin A
complex for calcineurin inhibition is purely by structural chance, as neither CsA or
cyclophilin A alone affects calcineurin activity (Hemenway & Heitman 1999). The
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cellular roles of the other cyclophilins are not well defined, and the calcineurinindependent effects of CsA binding to these cyclophilin proteins are not well known.
The binding of CsA to cyclophilin D, a mitochondrially targeted PPI family
member, has been well characterized (Friberg et al. 1998). Cyclophilin D is a part of the
mitochondrial permeability transition pore (MPTP), a large calcium-responsive complex
spanning the mitochondrial inner and outer membrane.
The structural components of the MPTP is a subject of debate and the latest
proposed model is illustrated in Figure 1.3; the voltage-dependent anion channel (VDAC)
has been proposed as the outer membrane subunit and either the adenosine nucleotide
translocase (ANT) or the mitochondrial phosphate carrier (PiC) have been proposed as
the inner mitochondrial membrane subunit (Halestrap 2009). Hexokinase and translocator
protein (TSPO, also known as peripheral benzodiazepine receptor) are also thought to be
part of the MPTP (Brenner & Moulin 2012). Genetic deletions of these various
components, however, does not result in mitochondrial permeability phenotypes,
(Brenner & Moulin 2012), illustrating the controversy of the MPTP identity. Most
recently, the c-subunit ring of the ATP synthase is highlighted as the putative inner
mitochondrial membrane channel portion of the MPTP (Alavian et al. 2014). The
structural identity of the MPTP remains an active area of research, and only cyclophilin
D is agreed upon as an obligatory pore component.
Despite the ambiguity of MPTP structural identity, its function is well known.
The MPTP is triggered to open by mitochondrial matrix calcium and its sensitivity to
calcium-induced opening can be affected by multiple factors. Stressors, such as apoptotic
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stimulus, low ATP (Crompton 1999), UV irradiation (Norman et al. 2010), high pH, and
high mitochondrial reactive oxygen species (ROS) increases the sensitivity of the MPTP
to calcium-induced opening. Opening of the MPTP leads to equilibration of
mitochondrial contents such as ROS, calcium, and other small molecules (<1.5kDa)
across the mitochondrial membranes. This subsequently results in mitochondrial osmotic
imbalance and swelling (Halestrap 2009).
The MPTP is believed have multiple physiological functions. As mitochondria
age, mutations accumulate in the mitochondrial DNA, which encodes components of the
electron-transport chain. Over time, the mitochondrial bioenergetic circuit becomes
progressively uncoupled, leading to elevated ROS production, ion imbalances, and low
ATP:ADP ratio. These signals can promote MPTP opening, which then causes
destruction and removal of the unhealthy mitochondria (Wallace 2005). This process
selectively removes old or unhealthy mitochondria from a cell. If occurring on a more
widespread, cell-wide scale, it can also contribute to cell death. In those incidences,
Bax/Bad megachannels can form on the swollen mitochondria, leading to cytochrome c
release as part of the apoptotic cascade.
Cyclophilin D plays a central role in regulating MPTP opening. Loss of
cyclophilin D raises the stimulus threshold required to open the pore. CsA treatment
phencopies cyclophilin D deletion and also results in decreased pore opening in response
to stimulus. It’s not entirely clear how CsA binding to cyclophilin D affects its regulation
of the MPTP, but it may occur through inhibition of the catalytic PPI activity of
cyclophilin D (Halestrap & Davidson 1990), which has been shown to be important in
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MPTP opening (Machida et al. 2006). CsA treatment consistently increases the apoptotic
threshold of cells, and this off-target effect of CsA has been exploited experimentally to
investigate mitochondrial function and apoptosis. Since mitochondrial content efflux is a
major component of ischemia-perfusion injury, inhibition of the MPTP by CsA in
cardiomyocytes decreases the severity of myocardial damage and is currently being
investigated as potential therapy for myocardial infarction (Piot et al. 2008).
Though CsA treatment decreases MPTP opening, the downstream effects on
mitochondrial biology and specifically ROS levels appear to be context-dependent.
Maintaining pore closure in the presence of an apoptotic stimulus impedes the release of
mitochondrial ROS. For example, CsA treatment decreases the efflux of mitochondrial
ROS in keratinocytes in response to UV irradiation (Norman et al. 2010). CsA treatment
in non-apoptotic conditions, however, leads to increased cellular ROS levels (O’Connell
et al. 2012; Longoni et al. 2001; Krauskopf et al. 2005).
The mitochondria is a major producer of endogenous ROS as it is a byproduct of
the electron transport chain (Adam-Vizi & Chinopoulos 2006). Endogenous ROS can
also be generated through specific enzymatic processes such as the NAD(P)H oxidase,
found in phagocytotic cells, endothelial cells, and smooth muscle cells (Touyz & Briones
2011).
In the body, ROS participates in the inflammatory response to neutralize
pathogens. They are also involved in the pathogenesis of many conditions such as
diabetes, atherosclerosis, and cancer (Bartosz 2009). ROS and other free radicals were
initially shown to be damaging to cellular components due to their unstable atomic
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structure, which causes protein and lipid oxidation and DNA damage. More recently,
however, ROS have also been shown to act as a signaling molecule at low levels (Bartosz
2009) and can affect a number of cellular processes, including mitogenic pathways
(Finkel 2011). In the circulatory system, ROS and the closely related molecules reactive
nitrogen species (RNS) are potent modulators of vascular tone (Yung et al. 2006; Maulik
& Das 2002). Therefore, endothelial cells are very sensitive to changes in ROS and RNS.
These compounds also affect endothelial cell junctions, which in turn alter vascular
permeability (Monaghan-Benson & Burridge 2009). Furthermore, ROS signaling has also
been shown to affect other processes such as angiogenesis by promoting endothelial cell
migration and proliferation (Maulik & Das 2002; Ushio-Fukai 2006).
We have shown that CsA treatment of endothelial cells promotes proliferation and
migration in a calcineurin-independent manner. CsA is known to induce a strong
calcineurin-independent effect by binding to the mitochondrially located cyclophilin D.
Mitochondrial contents such as reactive oxygen species can trigger a variety of signaling
pathways in the vasculature, including pro-angiogenic effects. Therefore, we hypothesize
that CsA exerts a pro-proliferative and migratory effect in endothelial cells by stimulating
the production of mitochondrial ROS.
Here we show that treatment of endothelial cells with the non-immunosuppressive
cyclosporin analog NIM811 phenocopies the effects of CsA. Furthermore, CsA treatment
increases mitochondrial ROS levels and is associated with an increase in mitochondrial
membrane potential. Antioxidant co-treatment with CsA abrogates the pro-proliferative
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and migratory effects induced by CsA in vitro and decreases CsA-induced tumor growth
in vivo.
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Results

Cyclosporin A increases endothelial cell proliferation and migration via its interaction
with cyclophilins
We showed previously that CsA is able to promote proliferation and migration of
endothelial cells in the absence of calcineurin. Since CsA is not known to have
cyclophilin-independent effects, we speculated that this calcineurin-independent effect of
CsA is derived from its binding with other cyclophilin proteins. To test this hypothesis,
we utilized NIM811, a non-immunosuppressive cyclosporin analog that is unable to bind
calcineurin, but has similar binding profiles to cyclophilin proteins as CsA. In a manner
similar to CsA, NIM811 interacts with the well-characterized cyclophilin D and it is often
used as a research tool to study cyclophilin D and MPTP biology.
Using WT endothelial cells, we compared the effect of NIM811 to CsA on
endothelial proliferation. Dose-response proliferation curves for both drugs were bellshaped (Fig. 3.1A) after six days of treatment; low concentrations of CsA or NIM811
(10nM – 1µM) increased endothelial cell numbers whereas higher concentrations (≥1µM)
decreased cell numbers. Treatment with low concentration of either NIM811 or CsA
increased endothelial cell growth over time compared to vehicle treated controls (Fig.
3.1B). Furthermore, both CsA and NIM811 increased endothelial cell migration through
a transwell filter (Fig. 3.1C). The comparable growth and migratory phenotypes
following CsA and NIM811 treatment suggest that both molecules affect a common
pathway.
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Fig. 3.1. CsA and NIM811 promote endothelial cell proliferation and migration
in vitro. (A) Proliferation of primary murine endothelial cells in response to
increasing concentrations of CsA or NIM811. Cell numbers were counted after 6
days of treatment, n=3. (B) Proliferation of endothelial cells treated with 0.25µM
CsA, 0.1µM NIM811, or vehicle. Cell numbers were counted every other day. * P
<0.05 (between vehicle and CsA, and between vehicle and NIM811). Results are
representative of two experiments, n=3 per group. (C) Representative images of
endothelial cells migrating through a transwell filter in response to 0.25µM CsA,
0.1µM NIM811 or vehicle alone. Quantification of cell numbers per high-powered
field (hpf) is shown below. Results are pooled from two experiments. Error bars
indicate SEM, and * P <0.05 for all experiments. Scale bars indicate 100µm.

Cyclosporin A treatment increases mitochondrial ROS
Mitochondrial-derived ROS have been demonstrated to affect a number of
cellular processes including cell growth (Hamanaka & Chandel 2010) and adhesion
(Zhang & Gutterman 2007). We hypothesize that CsA treatment leads to an increase in
mitochondrial ROS, leading to the observed endothelial cell changes. The exact effects of
CsA on ROS are still unclear and may reflect differential MPTP activity in apoptotic vs.

61

non-apoptotic contexts. Therefore, we sought to determine the effects of CsA on
mitochondrial ROS in our experimental model.
Cellular ROS was measured using the commonly used ROS indicator DCFDA, a
broad nonspecific indicator of multiple reactive oxygen species. We found endothelial
cells treated with CsA showed no difference in DCFDA staining when compared to
vehicle treated cells (Fig. 3.2A).
While we expected to see an increase in cytosolic ROS following CsA treatment,
we hypothesized that the levels of ROS induced by the concentration of CsA we used
was low and non-damaging. Routinely used to measure the oxidative burst found in
neutrophils and macrophages, DCFDA may not have the sensitivity to detect the low
level of ROS generated by CsA in our system (Gomes et al. 2005). Additionally, the use
of DCFDA for the detection of overall oxidative stress has been undermined by its
inability to detect specific ROS (Myhre et al. 2003), such as H2O2 (in low peroxidase
contexts). To investigate the effect of CsA specifically on mitochondrial ROS, we stained
live cells with Mitosox, a mitochondrial targeted superoxide detector that fluoresces upon
superoxide binding and is a sensitive and specific indicator of mitochondrial superoxide
levels (Robinson et al. 2006), which can converted to the membrane permeant and
angiogenic H2O2 (Urao et al. 2013; Boveris & Cadenas 2000). When compared to
vehicle-treated cells, endothelial cells treated with CsA showed increased Mitosox
staining as detected by flow cytometry (Fig. 3.2B). Furthermore, endothelial cells treated
with NIM811 but not FK506 showed increased Mitosox staining when compared to

62

vehicle-treated controls (Fig. 3.2C). These results are consistent with our hypothesis that
CsA increases mitochondrial ROS in a calcineurin-independent manner.

Fig. 3.2. CsA increases mitochondrial superoxide production in endothelial cells.
(A) DCFDA fluorescence in endothelial cells treated with vehicle, 0.25µM CsA, or
H2O2, n=3-4 per group. (B, C) Mitosox fluorescence in endothelial cells treated with
vehicle, (B) 0.25µM CsA, (C) 0.1µM NIM811, or 0.1µM FK506 for 24 hours, and
then stained with 5µM Mitosox. Mitosox fluorescence was quantified by flow
cytometry. Quantification of mean fluorescence intensity (MFI) is shown, n=4-5 per
group. Error bars indicate SEM, and * P <0.05 for all experiments.

Cyclosporin A treatment increases mitochondrial membrane potential
While we and other groups have demonstrated that CsA increases ROS, the
mechanism by which this occurs is not completely understood. It is known that CsA
decreases MPTP opening in response to apoptotic stimuli, reducing the efflux of
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mitochondrial contents, including ROS. It is less clear how CsA increase ROS in the
absence of these stimuli.
The MPTP is a nonselective calcium and ROS-responsive channel bridging the
mitochondrial inner and outer membrane and is well known for its role in propagating
cell death (Halestrap 2009). This opening is irreversible and spreads to neighboring
MPTP complexes, causing depolarization waves across the mitochondrial membrane and
collapsing the mitochondrial membrane potential. This irreversible MPTP activity is
well-characterized in pathological settings, such as ischemia-reperfusion injury in
cardiomyocytes and hypoglycemia-triggered neuronal cell death (Crompton 1999). More
recently, the MPTP also has been shown to function under physiological conditions. In
this state, the MPTP undergoes individual reversible openings that recover quickly
without membrane depolarization or mitochondrial swelling (Halestrap 2009; Rasola et al.
2010; Wang et al. 2012; Wang et al. 2008). This mode, termed “physiological flickering”
or “superoxide flash,” is thought to have signaling or metabolic functions (Rasola et al.
2010). One consequence of a superoxide flash is a brief dip in mitochondrial membrane
potential, followed by recovery upon MPTP closure (Wang et al. 2012; Kowaltowski et
al. 2000). Therefore, physiological flickering of the MPTP may act as a potential releasevalve for regulating the mitochondrial membrane potential.
The mitochondrial membrane potential is closely linked to mitochondrial
metabolism, and studies in isolated mitochondria have shown a direct correlation between
the mitochondrial membrane potential and mitochondrial ROS production (Korshunov et
al. 1997). Thus, we hypothesize that during non-apoptotic conditions, CsA increases ROS
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by acting on the MPTP to decrease physiological flickering, resulting in increased
mitochondrial membrane potential, leading to increased mitochondrial ROS production.
To test this hypothesis, we utilized tetramethylrhodamine ethyl ester (TMRE), a
cationic fluorescent dye that is readily sequestered by active mitochondria. Due to its
cationic nature, the binding of TMRE to the mitochondria is membrane potentialdependent (Wang et al. 2008). Endothelial cells treated with either CsA or NIM811 for
48 hours showed substantially increased TMRE staining compared to vehicle treatment
(Fig 3.3.). These data are consistent with the hypothesis that CsA increases mitochondrial
ROS by increasing mitochondrial membrane potential.

Fig. 3.3. CsA treatment increases mitochondrial membrane potential in
endothelial cells. TMRE fluorescence in endothelial cells treated with vehicle,
0.25µM CsA, 0.1µM NIM811 for 24 hours, and then stained with 100nM TMRE to
detect mitochondrial membrane potential. TMRE fluorescence is detected by flow
cytometry, quantification of mean fluorescence intensity is shown on the right with
n=3-5 per group. Error bars indicate SEM, and * P <0.05.
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Antioxidant treatment abolishes the pro-angiogenic effect of cyclosporin A on
endothelial cells in vitro.
While our data show that CsA increases mitochondrial ROS in endothelial cells, it
is unclear whether the elevated ROS is responsible for the pro-angiogenic effects
observed. ROS is known to be involved in angiogenesis as VEGFR activation result in
NAPDH oxidase stimulation, which increases intracellular levels of the mitogenic H2O2,
leading to endothelial cell proliferation and migration (Ushio-Fukai 2006).
We hypothesize the CsA-induced ROS are responsible for the proliferative and
migratory effect observed in CsA-treated endothelial cells. To test this hypothesis, we
utilized both cellular and mitochondrial antioxidants to quench ROS. Co-treatment of
endothelial cells on CsA therapy with the cellular antioxidant N-acetyl-cysteine (NAC)
abolishes CsA-induced proliferation in vitro (Fig. 3.4.A). NAC treatment alone had no
effect on either wild type or Dscr1 transgenic endothelial cells, which overexpress the
endogenous calcineurin inhibitor DSCR1. Co-treatment with the mitochondrially
permeant superoxide dismutase mimetic and peroxynitrate scavenger
manganese(III)tetrakis(4-benzoic acid)porphyrin chloride (MnTBAP) also attenuates
CsA-induced proliferation (Fig.3.4.B). Treatment with both NAC and MnTBAP
decreased CsA-induced migration (Fig.3.4.C & D). Mitosox staining confirms that
MnTBAP co-treatment with CsA reduces mitochondrial generated ROS (Fig.3.4.E).
These results are consistent with the hypothesis that CsA promotes angiogenesis through
a ROS-dependent mechanism.
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Fig. 3.4. Antioxidant treatment abolishes cyclosporin A-induced endothelial cell
activation, A-D. (A, B) Proliferation of primary endothelial cells after treatment
with 0.25µM CsA plus (A) 5mM NAC, or (B) 10µM MnTBAP. Cell numbers were
counted daily. * P <0.05 (between CsA and CsA + antioxidant groups). Results are
representative of two experiments, with n=3 per group. (C, D) Representative images
of endothelial cells migrating through a transwell filter in response to vehicle,
0.25µM CsA, (C) 5mM NAC, or (D) 10µM MnTBAP. Black scale bars indicate
100µm. Quantification of cell numbers per high-powered field (hpf) is shown below.
Results are pooled from two experiments. (E) Quantification of Mitosox fluorescence
in endothelial cells treated with vehicle or 0.25µM CsA for 24 hours with 10µM
MnTBAP co-treatment.
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Antioxidant treatment in melanoma tumor models decreases cyclosporin A-induced
tumorigenesis
Our experiments show that CsA treatment leads to increased endothelial cell
proliferation and migration, which can be abolished with antioxidants. These results raise
the possibility of in vivo therapy with antioxidants to treat CsA-associated cancers. NAC
is an FDA approved drug commonly used as a mucolytic agent or to treat acetaminophen
toxicity. In the body, NAC is converted to a precursor of the cellular antioxidant
glutathione; external administration of NAC augments and boosts cellular antioxidant
capabilities (Samuni et al. 2013). Clinically, NAC is well tolerated in single, intermittent,
(Atkuri et al. 2007) or chronic use (Grandjean et al. 2000).
We sought to determine whether antioxidant therapy has an effect on CsA-

Fig. 3.5. Antioxidant treatment abolishes cyclosporin A-induced tumorigenesis in
vivo. Tumor growth over time in mice treated with or without CsA and with or
without 40mM NAC. WT C57/BL6 mice were supplied with NAC for 14 days, and
then treated daily with 10mg/kg CsA for 14 days before inoculating subcutaneously
with B16-F10 melanoma cells. Animals were maintained on CsA and or NAC
treatment for the duration of the experiment. Tumor volume was measured on the
indicated days. * P <0.05 (between CsA and CsA + NAC groups). Representative
experiment shown from two experiments, n=5-9. Error bars indicate SEM, and * P
<0.05 for all experiments.
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associated tumorigenesis in vivo using the B16-F10 allograft melanoma model in WT
mice. Oral NAC was delivered to mice in the drinking water at 40mM, a routinely used
investigational dose (Aoi et al. 2014). NAC co-treatment in tumor-bearing mice on CsA
therapy decreased tumor growth compared to CsA alone (Fig.3.5.). Tumor growth in
mice on NAC and CsA co-treatment were indistinguishable from untreated mice. NAC
treatment by itself also did not affect tumor growth. These data demonstrate the
significance of CsA-induced ROS in an in vivo tumor model and the therapeutic potential
for prophylactic prevention of CsA-induced tumorigenesis by administering antioxidants.

Cyclosporin A increases ERK signaling in a ROS-dependent manner
In endothelial cells, ROS can differentially affect numerous pathways depending
on the particular ROS agent, its concentration and location (Maulik & Das 2002). Given
the integration of ROS signaling in many essential endothelial cell processes, it is unclear
which pathways CsA affects to promote ROS-dependent pro-angiogenic effects.
To determine which pro-proliferative pathway CsA-induced ROS affects in
primary endothelial cells, we assessed for activation in the mitogenic AKT and MAPK
pathways and found that CsA treatment increased ERK but not AKT phosphorylation
(Fig.3.6.A). Pre-treatment of endothelial cells with NAC prior to CsA treatment
abolished CsA-induced ERK phosphorylation (Fig. 3.6.B), indicating this is a ROSdependent process. These data suggest that CsA-induced ROS promotes MAPK activity.
ROS can change the oxidative-reductive state in a cell, affecting the enzymatic
activity of proteins such as phosphatases, including those involved in mitogenic pathways
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(Forman et al. 2004; Thannickal & Fanburg 2000). Low levels of ROS have been shown
to deactivate phosphatases that negatively regulate mitogenic intermediaries, resulting in
prolonged proliferative signaling (Meng et al. 2002). Consistent with this notion, we
found that CsA treatment in endothelial cells prolonged ERK activation over time

Fig. 3.6. Cyclosporin A-induced reactive oxygen species upregulates MAPK
signaling. (A) Western blot of phospho and total ERK and AKT protein in endothelial
cells after treatment with 0.25µM CsA or vehicle for 5min. (B, C) ERK
phosphorylation in endothelial cells was examined by Western blot after treatment
with (B) 5mM NAC for 30 min followed by 0.25µM CsA or vehicle for 5min, or (C)
0.25µM CsA or vehicle for the indicated time. Phosphoproteins were normalized to
their respective total protein levels with relative expression levels on the right for all
experiments. (A-C) each lane is an individual experiment. Results are pooled from 4-5
experiments. Error bars indicate SEM, and * P >0.05 for all experiments.
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compared to vehicle treatment (Fig.3.6.C). Treatment with the supra-physiological
5ng/mL EGF (physiological range: 10-12g/mL (Joh et al. 1986)) was used as a positive
control to demonstrate both ERK activation as well as its decline over time.
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Discussion

In Chapter 2, we showed that CsA promotes endothelial cell proliferation and
migration in a calcineurin-independent manner. Here we argue that CsA achieves these
effects through elevated mitochondrial ROS. In these experiments, we demonstrate that
CsA and its non-immunosuppressive analog, NIM811, both act on the mitochondria to
increase mitochondrial ROS and promote endothelial cell proliferation and migration.
Neutralization of elevated ROS by either cellular or mitochondrial targeted antioxidants
abrogates CsA-induced endothelial cell proliferation and migration. Prophylactic
antioxidant treatment in tumor-bearing mice on CsA regimens significantly reduces the
increased tumorigenesis seen with CsA treatment. In vitro studies in endothelial cells
showed that CsA promotes ERK phosphorylation in a ROS dependent manner.
A number of calcineurin-independent effects have been ascribed to CsA. CsA has
been shown to increase p38 and JNK signaling in T cells (Matsuda et al. 2000) and
inhibit mitochondrial calcium uptake in HeLa cells (Montero et al. 2004), effects not
shared by other calcineurin inhibitors, either pharmacological or endogenous. CsA has
previously been shown to bind and inhibit P-glycoprotein (Morjani & Madoulet 2010).
Brain and testis endothelial cells express high levels of P-glycoprotein in order to
maintain the blood-brain or blood-testis barrier. Tumor cells can also express Pglycoprotein as a means of drug resistance (Morjani & Madoulet 2010), however, this
does not always extend to tumor endothelial cells (Tóth et al. 1996). Moreover, our
experiments utilized lung endothelial cells, which do not express P-glycoprotein
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(Demeule et al. 2001). Therefore, we do not expect the inhibition of P-glycoprotein by
CsA to be a confounding factor in our results.
While we show that antioxidant treatment of tumor-bearing mice in vivo
decreases CsA-induced tumor growth, it is still unclear whether this is due to a decrease
in tumor angiogenesis. This ambiguity could be addressed by staining for endothelial cell
markers such as CD31 to reveal whether antioxidant treatment has any effect on CsAinduced tumor angiogenesis.
Oral ingestion of both CsA and NAC results in elevated drug levels in both tumor
cells as well as the tumor microenvironment, all of which may also affect tumor
angiogenesis. We have shown in vitro that CsA elicits pro-angiogenic responses directly
in endothelial cells, but have not excluded the possibility that it may also act in a tumor
cell-autonomous manner in vivo to induce angiogenesis as tumor-derived ROS can also
promote neoplastic angiogenesis (Xia et al. 2007). Likewise, systemic administration of
NAC could be affecting both the tumor tissue and also the tumor microenvironment.
Since we postulate that CsA promotes ROS in a cyclophilin D-dependent manner in
endothelial cells, the deletion of cyclophilin D in the host tissue should abrogate the
effects of both CsA and antioxidant treatment on tumorigenesis. Utilizing a whole body
cyclophilin D knockout transgenic mouse model would address whether CsA-induced
effects are tumor cell autonomous or microenvironment based. Similarly, transgenic mice
with conditional deletion of cyclophilin D specifically in endothelial cells could be used
to determine whether CsA-induced tumorigenesis occurs only through its activity in
endothelial cells.
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CsA has not been described to have any cyclophilin-independent effects. Scant
functional characterization of some cyclophilin proteins has been performed, but their
specific functions are mostly unknown. Correspondingly, the effect of CsA binding to
these proteins is unknown. An exception is cyclophilin D, where both its function and
interaction to CsA has been thoroughly studied with biological relevance in multiple
disease models (Giorgio et al. 2010; Elrod & Molkentin 2013). Since the effect of the
CsA-cyclophilin D interaction on mitochondrial biology is well known, cyclophilin D is
an attractive candidate as a calcineurin-independent mechanism responsible for the proangiogenic effect of CsA in endothelial cells. However, NIM811 and CsA still bind to
other intracellular cyclophilins. Therefore, the possibility of other CsA binding partners
contributing to this effect cannot be ruled out and will be discussed in further detail in
chapter 4.
While we suspect that CsA acts through a ROS-dependent mitochondrial
mechanism to increase endothelial cell proliferation and migration, we have not
completely ruled out the contribution of ROS-independent mitochondrial effects. We did
establish that CsA has no effect on cell death in the absence of apoptotic stimulus, as it
known that CsA decreases apoptosis under cell death conditions (Norman et al. 2010).
The effects of CsA-cyclophilin D interaction on other mitochondrial functions were not
addressed in this study and future studies assessing mitochondrial metabolism, calcium
signaling, fission/fusion, and mitophagy would be helpful in tackling this concern.
Our data shows elevated Mitosox but not DCFDA staining in endothelial cells
following CsA treatment. We hypothesize that CsA leads to an increase in the production
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of mitochondrial ROS, which could enter the cytosol in the membrane-permeant form
H2O2 to affect cellular redox signaling. Therefore, we expected to see elevated ROS
levels in both compartments. As DCFDA staining shows no change with CsA treatment,
it suggests cellular ROS levels are unchanged. However, the DCFDA marker may not be
a representative readout of cytosolic ROS. Upon entering a cell, cleavage of DCFDA by
cellular esterases converts it into a non-fluorescent ROS indicator, which becomes
fluorescent when oxidized. This intracellular ROS probe is sensitive to oxidation by
peroxyl, alkoyl, NO2, carbonate, and OH∙ radicals, but not to O2- or H2O2 (in the absence
of peroxidases) (Eruslanov & Kusmartsev 2010). H2O2 is a relatively stable ROS family
member which can diffuse freely across membranes such as the mitochondrial membrane
and has been implicated in physiological processes such as proliferation and growth
arrest (Giorgio et al. 2007). The unreliability of the DCFDA probe to detect H2O2 causes
it to be a less relevant indicator of the specific reactive oxygen species that may be
responsible for the proliferative changes studied here. The addition of horseradish
peroxidase or myeloperoxidase, which oxidizes DCFDA in the presence of H2O2, would
allow us to determine the total cytosolic ROS in a cell. Alternatively, other hydrogen
peroxide indicators such as Amplex Red (in combination with horseradish peroxidase) or
Peroxy Green 1 and Peroxy Crimson 1 (Miller et al. 2007) could also be used.
The mitochondrial membrane potential, which contributes to the proton-motive
force to drive the regeneration of ATP from ADP, is generated and maintained by the
oxidative-phosphorylative chain. Changes in the mitochondrial membrane potential can
significantly affect mitochondrial bioenergetics, including the production of reactive
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oxygen species from the ox-phos chain. Increasing the mitochondrial membrane potential
through chemical means increases the production of hydrogen peroxide from the
mitochondria (Korshunov et al. 1997). Our studies indicate that this is a mechanism by
which CsA could potentially stimulate mitochondrial ROS production. This concept, as
well as the background concerning relevant mitochondrial bioenergetics, are complex and
will be discussed in depth in the summary chapter.
While our data is consistent with the hypothesis that the increased mitochondrial
potential is the cause of CsA-induced ROS, but we have not ruled out other potential
means responsible for elevated ROS. A previous study in endothelial cells found that
CsA treatment perpetuated ROS damage by inactivating the mitochondrial antioxidant
manganese superoxide dismutase through an endothelial cell nitric oxide synthetasedependent mechanism (Redondo-Horcajo et al. 2010). Additionally, CsA has been shown
to upregulate the expression of TXNIP, an inhibitor of the ROS scavenger thioredoxin, in
renal mesangial cells (O’Connell et al. 2012). It is possible that all these sources could
potentially contribute to CsA-associated ROS elevation, and future studies examining the
effect CsA on each pathway in a single system would help evaluate the contribution of
each of these ROS-producing pathways to CsA-associated ROS elevation.
The major physiological source of ROS in endothelial cells is from the NADPH
oxidase, where it is produced in response to pro-angiogenic stimulus (Maulik & Das
2002). ROS serves as a signaling molecule which can induce VEGF receptor
autophosphorylation, c-Src activation, and VE-cadherin phosphorylation (Ushio-Fukai &
Nakamura 2008). Additionally, ROS by itself can induce VEGF expression (Xia et al.
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2007). The studies presented here did not assess whether CsA-induced ROS has any
effect on endogenous ROS-activated endothelial cell processes. Characterization of
VEGF expression levels and downstream signaling using NIM811 (to bypass the effect of
CsA on the VEGF-calcineurin-NFAT axis) and antioxidants would address this point.
Our data showed that CsA treatment leads to prolonged activation of the MAPK
effector ERK1/2 in vitro, which is highly suggestive that CsA may act to reduce its
negative regulation, but does not show a causal relationship. Probing the activity of the
mitogen-activated protein phosphatases (MKP1-10) with CsA and antioxidant treatment
would help fill in the gap in knowledge. Furthermore, future experiments examining and
manipulating the downstream ERK1/2 effectors are needed to show a direct effect of
CsA-induced ERK activation and CsA-induced proliferative changes.
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CHAPTER 4: SUMMARY AND DISCUSSION
Summary of findings: overview
In this thesis, we have identified a novel effect of the commonly used
immunosuppressant cyclosporin A (CsA) in tumor angiogenesis. CsA is a potent inhibitor
of the calcineurin pathway, which is involved in immune defense, memory consolidation,
cardiovascular biology, and angiogenesis (Rusnak & Mertz 2000; Liu et al. 1991; Graef
et al. 2001; Molkentin et al. 1998; Miyakawa et al. 2003). Our lab previously
demonstrated that suppression of calcineurin in endothelial cells by its endogenous
inhibitor Down Syndrome Candidate Region 1 (DSCR1) results in suppression of tumor
angiogenesis and tumor growth (Baek et al. 2009). Paradoxically, chronic therapy with
the calcineurin inhibitor CsA for transplant patients is associated with increased tumor
incidence and progression. Here, we demonstrate for the first time that CsA treatment
promotes tumor angiogenesis in vivo as well as endothelial cell proliferation and
migration in vitro. We found that the pro-proliferative and migratory effects of CsA in
endothelial cells occur in a calcineurin-independent manner, and is associated with
increased mitochondrial reactive oxygen species (ROS). Additionally, treatment with
antioxidants decreased CsA-induced proliferation and migration in vitro and CsAinduced tumorigenesis in vivo. Our model is summarized in figure 4.1.
Our studies have uncovered a previously unknown and targetable pathway
through which CsA promotes tumorigenesis. However, our results raise many new
questions, which will be discussed in the following pages along with future directions.

78

Fig. 4.1. Proposed model of CsA-induced tumor angiogenesis. CsA treatment in
endothelial cells induces mitochondrial ROS in a calcineurin-independent manner,
which promotes cell migration and proliferation. Increased endothelial cell
proliferation and migration due to CsA treatment leads to increased tumor
angiogenesis. Calcineurin (grey) inhibition still occurs, but the pro-proliferative
effects of CsA is due to mitochondrial ROS.

CsA, cancer, and angiogenesis

Transplant-associated cancers: beyond skin cancers
To accurately reflect on the cancer profile of patients on CsA therapy, we utilized
skin cancer models to study the effects of CsA on tumorigenesis. Most studies of CsA79

associated cancers also examine CsA in the context of skin tumorigenesis. There are a
scattering of studies, however, that investigates the effects of CsA primarily on renal
carcinoma or lymphocytes (Datta et al. 2009; Hojo et al. 1999; Mazière et al. 2005). A
study by Guba et al in 2007 examined the risk of malignancy after kidney transplant in
2419 transplant patients and found an elevated risk of skin cancers, but also a 17.6-fold
increase in the relative risk of developing kidney cancer (Wimmer et al. 2007). This was
similarly mirrored by another study in 35,000 kidney transplant patients, who had a 15fold increase in relative risk of kidney cancer (Kasiske et al. 2004). This elevation in
kidney cancers in kidney transplant patients may be due to the kidney as the transplanted
organ, as there is an organ-specific cancer risk arising from the transplanted organ
(Engels et al. 2011).
Non-hogkins lymphoma in transplant patients is termed posttransplant
lymphoproliferative disorder (PTLD) (Engels et al. 2011), and is associated with
reactivation of latent Epstein-Barr virus and T cell dysfunction, presumably due to
immunosuppression. PTLD often resolves upon discontinuation or reduction of
immunosuppressive therapy, but can be also treated with radiation or chemotherapy (Tsai
et al. 2001; Gottschalk et al. 2005).
Since kidney cancers are associated with an organ-specific etiology, and PTLD is
strongly tied to immunosuppression, skin cancers appear to best represent a direct
oncogenic effect of CsA treatment. Therefore, we conducted our study on CsA
specifically in the context of skin cancers. Nonetheless, one should not marginalize the
morbidity and mortality of non-skin solid tumors in organ transplanted patients.
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Thorough investigation of the pathogenesis behind those tumors is important for
decreasing the incidence and for the development of therapies.

Cancer cell autonomous effects of CsA on tumorigenesis: CsA and ROS on tumor cells.
The direct effect of CsA on tumor cells have been examined by other groups and
described earlier in Chapter 1 and summarized in Figure 2.0. CsA is known to promote
TGF-β production and Ras signaling in transformed tumor cells, induce ATF3 expression,
and suppress DNA repair proteins and UV induced apoptosis in keratinocytes (the tumor
cells of origin).
Our studies show CsA can act on the tumor microenvironment, specifically
endothelial cells, through a ROS-dependent manner to increase cell proliferation and
migration. Reactive oxygen species are often elevated in tumors and can affect a number
of tumorigenic pathways in a cell-autonomous manner.
ROS molecules are highly reactive can interact with DNA, leading to DNA
damage. If left unrepaired or mis-repaired, this DNA damage results in mutations, paving
the way for oncogenic transformation.
ROS can also regulate various mitogenic signaling pathways through redox
signaling. The MAPK pathway, which was demonstrated to be activated by CsA in
endothelial cells, is overactive in many cancers. Elevated ROS in cancer cells has been
shown to augment MAPK signaling, promoting tumor cell proliferation in a cell
autonomous manner (Weinberg et al. 2010; Pelicano et al. 2004). ROS can also affect
redox-sensitive transcription factors, for example, NF-κB and HIF-1α, which are
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important in tumorigenesis (Bonello et al. 2007). Additionally, p53, a critical tumor
suppressor, forms disulfide bonds when oxidized that interfere with its ability to bind to
p53 response elements, negatively affecting its transcriptional activities (Sun et al. 2003).
It is important to note that the relationship between ROS and tumorigenesis is
complex, as it has also been found to negatively affect tumorigenesis. Radiation therapy
exerts its tumoricidal effect by generating high levels of ROS. Elevated ROS has also
been shown to lead to p38-dependent apoptosis in the setting of oncogene activation
(Dolado et al. 2007). Therefore, while CsA-induced ROS in cancer cell could potentially
lead to increased tumor growth, its actual contribution to tumorigenesis needs to be
evaluated.

Non-cancer cell autonomous effects of CsA on tumorigenesis: immune cells and
fibroblasts
We show that CsA promotes tumorigenesis through its effect on endothelial cells.
The tumor microenvironment is a diverse milieu with multiple cell types which can affect
tumorigenesis. Therefore, it is important to consider that CsA may also affect these other
cell types to indirectly influence tumorigenesis.
Immune cells infiltrate tumors and secrete a number of inflammatory regulators.
As CsA inhibits calcineurin-dependent T cell activation, it potently suppresses the
adaptive immune response. It has been postulated that loss of immunosurveillance due to
CsA treatment is a means by which transformed tumor cells can escape suppression by
the immune system. Additionally, immunosuppression may also allow the unchecked
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activity of oncogenic viruses. This is supported by greater HPV presence, which can
cause skin cancers, in CsA-associated squamous cell carcinomas (Queille et al. 2007).
However, no studies have shown a direct causal link between HPV and CsA-associated
cancers, or whether they are two independent consequences of CsA therapy.
Cancer immunity is a complicated and multifactorial interaction between immune
cells, tumor cells, stromal and endothelial cells. Immune cells can both antagonize and
promote tumor growth. Generally, prolonged presence of activated innate immune cells
such as neutrophils and macrophages is seen as pro-cancerous. However, innate immune
cells are also under regulation by the adaptive immune system, which has paradoxical
effects on tumorigenesis that can vary depending on cancer type, cancer progression, cell
type, and experimental conditions (de Visser et al. 2006). So while suppression of
adaptive immune cells in the tumor microenvironment by CsA is likely to affect
tumorigenesis, it is unknown what the effect is. Comparing the effects of CsA with other
immunosuppressants such as rapamycin or corticosteroids on tumor growth in
immunocompetent and immunodeficient mouse models would be helpful in delineating
the immunosuppressive contribution of CsA to tumorigenesis.
A large component of the tumor microenvironment is fibroblasts, often referred to
as carcinoma-associated fibroblasts (CAF). These CAFs are poorly understood, including
their cells of origin, but are believed to promote oncogenic signals to tumor cells. The
effects of CsA on CAFs are not known. CsA has been shown to promote TGF-β
production in tumor cells, which may activate fibroblasts to a CAF-like phenotype.
However, unpublished data in our lab shows calcineurin activity may be important in
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TGF-β stimulated fibroblast activation, and inhibition of calcineurin by CsA prevents
fibroblast activation. It would be interesting to determine the cumulative effect of CsA on
the stromal fibroblasts and the fibroblast mediated contribution of CsA to tumor growth.

Functional effect of CsA on tumor angiogenesis
Given the disorganized nature of tumor vasculature, the pattern of CD31 positive
structures in CsA treated tumors is by no means reflective of more functional vessels, but
suggests an increase in nutrient or oxygen delivery that could provide a benefit to solid
tumors (Bergers & Benjamin 2003). Future experiments involving the injection of FITClectin or FITC-dextrin, fluorescent markers of vessel permeability, into the circulation of
tumor-bearing mice treated with CsA prior to harvesting would provide information on
the fluid flow and permeability of these tumor vessels. Furthermore, in vivo assessment
of tumor perfusion and oxygenation can be achieved through Doppler ultrasound or
electrodes (Eppendorf electrodes or Recessed Microelectrodes) (Menon et al. 2003)
Our studies show CsA treatment in vivo results in a higher number of short CD31
positive structures in xenograft tumors, and in vitro CsA promotes endothelial cell
proliferation and migration with no effect on matrigel tube formation. The data suggests
that CsA promotes the earlier stages of angiogenesis, specifically proliferation and
migration. Unlike physiological angiogenesis, the process of tumor angiogenesis places a
greater emphasis on endothelial cell proliferation and vessel elongation compared to
vessel remodeling and maturation (Nishida et al. 2006). Importantly, CsA treatment,
through the upregulation of ROS, may further aggravate the imbalance of pro- to anti84

angiogenic pathways, amplifying the dysfunctional but aggressive nature of tumor
angiogenesis. Future studies providing more detailed characterization of CsA-associated
vessels, such as the expression of angiogenic regulators VEGF, TSP-1, or activation of
Notch, would contribute more fully to our understanding of the role of calcineurin in
tumor angiogenesis.

Effect of CsA on angiogenesis: contribution of tumor cells
Tumor cells are able to exert changes in its microenvironment through either
secreted factors or cell-to-cell contact. The major secreted promoter of angiogenesis is
VEGF (Carmeliet 2005). CsA treatment in renal carcinoma cells has been shown to
directly promote the transcription and expression of VEGF (Basu et al. 2009). The
significance of VEGF in CsA-associated skin carcinoma in vivo would be an interesting
area to explore with the anti-VEGF antibody bevacizumab. . It is not clear whether CsAinduced VEGF production is due to calcineurin inhibition. Loss of calcineurin activity,
through genetic deletion or pharmacological inhibition, in tumor cells could be used to
evaluate the calcineurin-dependence of CsA-induced VEGF.
CsA also induces the production of TGF-β in tumor cells (Hojo et al. 1999).
While a potent enhancer of cancer metastasis, TGF-β also has been described to have
both pro- and anti-angiogenic effects. High levels of TGF-β is known to inhibit
angiogenesis but low levels of TGF-β signaling can promote endothelial cell proliferation
and enhance VEGF induced angiogenesis (Walshe 2010). Additionally, in nutrient
deprived contexts, TGF-β promotes endothelial cell survival (Lu 2008), which can
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provide an advantage in the harsh tumor microenvironment. Treating conditioned media
from tumor cells with neutralizing TGF-β antibodies prior to application to endothelial
cells in vitro would be helpful in determining the effects of tumor derived-TGF-β on
endothelial cells.
Although it is known that CsA treatment induces TGF-β production, it is unclear
whether it occurs through calcineurin-NFAT inhibition or through calcineurinindependent cyclophilin binding. There are NFAT and AP-1 binding sites present in the
TGF-β promoter (Nakano et al. 2007). Additionally, calcineurin-NFAT signaling has also
been shown to regulate a switch in the response to TGF-β, from cell cycle inhibitory to
proliferative (Singh et al. 2010). It is possible that CsA not only promotes TGF-β
production in tumor cells, but also regulates the response to TGF-β signaling.
While we found CsA increases ROS in endothelial cells, the phenomenon has also
been reported in other cell types, such as smooth muscle cells (Krauskopf et al. 2005) and
renal glomerular cells (O’Connell et al. 2012), suggesting it may be a common effect.
Tumor-derived ROS may affect angiogenesis in two ways. First, tumor derived ROS may
directly enter endothelial cells to promote angiogenic processes. . CsA treatment could
elevate ROS levels in multiple cells types, including tumor cells, which can diffuse out
into the surrounding environment, enter endothelial cells, and induce an angiogenic
response. This notion could be tested by measurement of intra-tumor and serum H2O2, a
stable and membrane permanent ROS,. .
Secondly, tumor-derived ROS has been shown to induce the transcription of proangiogenic factors such as VEGF (Xia et al. 2007). The angiogenic secretome in
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conditioned media from tumor cells treated with CsA, antioxidant, or combination of
both could be assessed using an antibody array to determine whether CsA affects
angiogenic factors in a ROS-dependent manner.
To determine the source of the ROS responsible for angiogenesis, overexpression
of antioxidant genes such as superoxide dismutase or catalase specifically in tumor cells
to quench tumor-derived ROS in a xenograft tumor model with CsA treatment would
help separate the source of ROS responsible for angiogenesis; whether it is tumor or host
derived.

Effect of CsA on angiogenesis: contribution of smooth muscle cells
In addition to the direct pro-proliferative and migratory effect of CsA on
endothelial cells, CsA may also promote tumor angiogenesis through its effect on other
cell types in the tumor microenvironment. In vascular smooth muscle cells, CsA has been
demonstrated to block proliferation and modulate the vascular smooth muscle cell
phenotype through a NFAT-independent mechanism (Garvey et al. 2010). The CsA
binding partner cyclophilin A is secreted by smooth muscle cells and is linked to
proliferation, vascular remodeling, and recruitment of inflammatory cells (Nigro et al.
2011). Vascular smooth muscle cells modulate tumor angiogenesis through regulation of
vessel diameter, permeability, and contractility, as well as by regulating endothelial cell
sprouting (Raza et al. 2010). CsA present in the tumor microenvironment may act upon
smooth muscle cells to contribute to the increased angiogenesis observed. Comparison of
pericyte markers such as α–SMA, NG2, desmin between tumors from CsA or vehicle
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treated mice, followed by in vitro characterization of vascular smooth muscle cells
treated with CsA would contribute to a more complete understanding of the contribution
of CsA-microenvironment effects towards tumor angiogenesis.

Differential effects of CsA on the vascular system: established vessels vs. new growth
Oral CsA treatment in transplant patients also results in other vascular side effects,
the most notable being systemic hypertension. As discussed previously, CsA-induced
hypertension is the consequence of several pathological changes including elevated
endotehlin-1, decreased nitric oxide, and activation of the renal angiotensin system
(Olyaei et al. 2001). Of note, the primary effect of CsA in the established adult
vasculature is an increase in vascular tone; excessive vessel sprouting or angiogenesis has
not been described. Physiologic adult vasculature is composed of mature and quiescent
endothelial cells, which are long-living with low proliferative potential (Bergers &
Benjamin 2003).
There appears to be a context-dependent response of endothelial cells to CsA
treatment. Our studies on proliferating endothelial cells and tumors demonstrate CsA
treatment further increases endothelial cell proliferation and angiogenesis, whereas in the
established quiescent vasculature, CsA treatment elevates vasculature tone leading to
hypertension. These different outcomes are dictated by unclear mechanisms, but may
allude to the differential responses between quiescent or activated endothelial cells to
ROS (Yung et al. 2006). In established mature vessels, redox signaling can cause
endothelial dysfunction, promote secretion of inflammatory cytokines, hinder
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vasorelaxation, or induce apoptosis (Yung et al. 2006). Furthermore, elevated ROS
oppose vasodilation by converting the vasodilatory nitric oxide into the inactive
peroxynitrite, diminishing the vasoactive capacity in the vascular wall (Yung et al. 2006).
In the context of pathologic angiogenesis, the pro-angiogenic regulator VEGF-A has been
shown to steer the direction of ROS signaling towards cell division and migration (Yung
et al. 2006; Ushio-Fukai 2006; Xia et al. 2007). Therefore, the tumor microenvironment
may provide a pro-angiogenic environment for CsA signaling whereas the same CsA
treatment in established vasculature results in hypertensive responses.

Calcineurin-independent effects of CsA

Untangling the pathways: small molecule inhibition of calcineurin and cyclophilins
Calcineurin Inhibitors: FK506 vs CsA
While the best studied target of CsA is calcineurin, CsA also interacts with other
molecules. Therefore, to determine whether calcineurin inhibition is responsible for CsAinduced proliferation and migration in endothelial cells, we compared the effects of
several other calcineurin inhibitors to CsA. Previous studies have shown that
overexpression of the endogenous inhibitor Down Syndrome Candidate Region-1
(DSCR1) suppresses VEGF induced angiogenesis by inhibiting the calcineurin pathway
(Baek et al. 2009; Hesser et al. 2004; Chan et al. 2005; Yao & Duh 2004; Iizuka et al.
2004). We showed that treatment with CsA in endothelial cells overexpressing DSCR1
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increased proliferation, suggesting CsA acts in a dissimilar manner to DSCR1. We also
compared the effects of CsA with the independent pharmacological calcineurin inhibitor,
FK506. Also known as tacrolimus, FK506 is a small molecule which binds to the
intracellular proteins FK Binding Proteins (FKBPs) to form a calcineurin-inhibitory
complex (Rusnak & Mertz 2000) that is distinct from the CsA-cyclophilin complex. The
only similarity between CsA and FK506 is the ability to inhibit calcineurin. Therefore,
FK506 should theoretically act as an excellent control to determine the calcineurindependence of the endothelial cell effects seen with CsA treatment.
We determined the calcineurin-dependence of the effects of CsA on endothelial
cells by comparing it to FK506. Treatment with the clinically relevant dose
0.15mg/kg/day of FK506 in vivo did not increase B16-F10 tumor growth compared to
control treatment, while treatment with CsA promoted tumor growth. FK506 treatment
decreased VEGF-induced migration, in direct contrast to CsA, which increased
endothelial cell migration. CsA, but not FK506, treatment increased endothelial cell
proliferation. Interestingly, treatment with FK506 inhibited endothelial cell growth, but to
a lesser magnitude than calcineurin inhibition via DSCR1 (Baek et al. 2009).
These data are consistent with our hypothesis that CsA promotes an endothelial
cell phenotype in a calcineurin independent-manner. As a calcineurin inhibitor, FK506 is
expected to vastly decrease endothelial cell proliferation compared to vehicle treated, but
the magnitude of its effect in these experiments, while significant, is paltry. This effect
may reflect an off-target effect of FK506 on FKBPs, which fall under the immunophilin
family of proteins (Barik 2006). FK506 binds to multiple FKBP family members, which
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has cellular roles that include calcium regulation(MacMillan 2013), and inhibition of
TGF-β signaling (Spiekerkoetter et al. 2013). The FKBPs are highly expressed in
endothelial cells (Higgins et al. 2003) and loss or inhibition of FKBPs in the vascular
compartment results in decreased nitric oxide production and increased TGF-β and BMP
signaling (Spiekerkoetter et al. 2013). The outcomes of TGF-β signaling in endothelial
cells can be variable depending on context, but have been shown to promote angiogenesis,
wound healing responses, and tube formation. Treatment with FK506, through
sequestering FKBPs, a negative regulator of TGF-β, could potentially enhance TGF-β
signaling in endothelial cells, opposing calcineurin inhibition, resulting in only a slight
depression in endothelial cell proliferation, as seen in our studies.
FK506 may also have a direct negative effect on tumor progression independent
of endothelial cells as a previous study found topical applications of FK506 inhibited
chemically-induced skin tumorigenesis and was associated with decreased IL-1α levels
(Yamamoto & Jiang 1994). These studies, along with our data, indicate that while FK506
and CsA are often considered comparable drugs clinically and experimentally, they are
indeed very different molecules which can have a myriad of unrelated calcineurinindependent effects. We show they have different effects on tumorigenesis, but this may
extend to other physiological effects as well. Therefore, the clinical side effect profiles of
these two drugs should be evaluated independently and their use in experimental studies
should take into consideration the dissimilar off-target effects.
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Cyclophilin inhibitors: NIM811 vs CsA
Due to the calcineurin-independent effects of FK506 and the possible
confounding factor of FKBP signaling, FK506 may not be an ideal control for
determining the calcineurin-dependency of the effects seen with CsA. Therefore, we then
used NIM811, a non-immunosuppressive cyclosporin analog. NIM811, along with
Alisporivir (DEB025), was originally developed as a potential therapy for hepatitis C,
which binds to cyclophilins as part of its viral life cycle (Hopkins & Gallay 2012).
NIM811 is identical in chemical structure to CsA with the exception of an extra methyl
group on amino acid 4 (Rosenwirth et al. 1994), rendering it unable to bind to calcineurin
and an ideal control to test the calcineurin-dependence of the effect of CsA on endothelial
cells. The binding of NIM811 to cyclophilin proteins are unchanged compared to CsA
and unaffected by this side group difference (Rosenwirth et al. 1994). When treated with
NIM811, endothelial cell proliferation increased in a manner comparable to when treated
with CsA. Both NIM811 and CsA treatment induced a similar bell-shaped growth curve,
showing both cyclosporin analogs exert the same dose-dependent effect on proliferation.
Additionally, NIM811 also promotes endothelial cell migration across a transwell filter.
These data are in accordance with the hypothesis that CsA promotes endothelial cell
proliferation and migration in a calcineurin-independent manner.

Cyclophilin inhibitors: clinical implications
These results clearly identify calcineurin-independent effects of CsA on
endothelial cells, but also raise questions regarding the clinical usage of CsA analogs.
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Non-immunosuppressive cyclosporin analogs are currently in development for treatment
of hepatitis C (hep C). Inhibition of cyclophilins with cyclosporins inhibits viral
replication. Three cyclosporin derived non-immunosuppressive cyclophilin inhibitors:
Alisporivir (Debio-025), SCY-635, and NIM811, are currently in investigation as
potential therapy for hep C (Hopkins & Gallay 2012). Our studies showing that the
cyclosporin analog NIM811 promotes endothelial cell proliferation highlights a potential
oncogenic risk with cyclophilin inhibitors similar to the effect seen with CsA. The
completed clinical trials of these cyclophilin inhibitors have not found an increase in
cancer risk or aberrant angiogenic events (Gunter et al. 2010). However, this may reflect
the duration of drug use in these trials, usually lasting 4 weeks or less. A Phase IIa trial
with Alisporivir lasting 48 weeks also did not identify increases in cancer risk or vascular
events (Alberti et al. 2012; JM et al. 2012). While its similarities to CsA label this
cyclophilin inhibitor as a potentially pro-tumorigenic drug, to the best of our knowledge,
we are the only group to study the effect of NIM811 on endothelial cells. So far no
clinical data has emerged which would cement an association between NIM811, or other
cyclophilin inhibitors, and increased cancer risk. As these cyclophilin inhibitors are still
investigational therapies, they have not yet been thoroughly tested in patient populations.
Additionally, transplanted associated cancers generally appear after years of continuous
treatment, a scenario which cyclophilin inhibitors have not yet been subjected to. The
cancer risk found with CsA treatment in transplant patients is dose dependent. Therefore,
given the nature of hep C treatment, which is shorter in duration than transplant
immunosuppression, the cumulative dose of cyclophilin inhibitor accrued over the
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duration of treatment may not be sufficient to affect cancer risk. Taken together, these
cyclophilin inhibitors, in their current clinical niche, do not appear to pose a significant
cancer risk. Nonetheless, our studies comparing CsA and NIM811 suggests additional
investigations into the safety of the cyclophilin inhibitors maybe warranted, especially in
regards to potential cancer risk.
An interesting finding from our studies was that both CsA and NIM811 treatment
induced a bell-shaped dose-dependent effect on endothelial cell growth in vitro.
Compared to vehicle treated controls, CsA and NIM811 caused an increase in endothelial
cell growth starting at 10nM and increased with drug concentration until a maximum of
250nM, then causes cytotoxicity at >1M. This data demonstrates the complexity of the
cellular response to these drugs, and possibly reflects the combined effect of more than
one affected pathway. At least two distinct and opposing effects on proliferation have
been ascribed to CsA in endothelial cells through two different pathways. We show CsA,
at low levels, promotes endothelial cell proliferation through a calcineurin-independent
and ROS dependent pathway. At high levels CsA inhibits endothelial cell migration,
tube formation, and corneal angiogenesis through calcineurin inhibition (Hernández et al.
2001). Additionally, ROS signaling can be either pro-mitogenic or pro-apoptotic
depending on its levels (Yung et al. 2006). The delicate balance in which CsA induces
multiple and sometimes opposing effects due to drug concentrations and cellular context
may explain the difficulty of managing its therapeutic window. While CsA has
revolutionized the transplant field by preventing graft rejection, its use is riddled with
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multiple severe side effects. Taking into consideration the literature as well as our studies,
clinical indications for CsA should instead consider other, more specific and safer drugs.

Calcineurin loss and cell migration
To determine whether CsA promotes angiogenesis in a calcineurin-dependent or
independent manner, we used the lox-stop-lox technology to create cells in which the
calcineurin B subunit can be genetically deleted, leading to the degradation of calcineurin
A and loss of calcineurin activity. Loss of calcineurin nearly completely abolished
endothelial cell migration across a transwell filter when compared to calcineurincompetent cells. While unexpected, this is not surprising given that calcineurin-NFAT
signaling promotes tumor cell migration and tumor invasion through integrin signaling
(Liu et al. 2010; Jauliac et al. 2002). Additionally, inhibition of calcineurin through
overexpression of DSCR1 (Iizuka et al. 2004) or treatment with FK506 decreased
migration in vitro. In endothelial cells, NFAT promotes endothelial cell migration
through upregulation of Cox-2 (Hernández et al. 2001). These studies indicate that
calcineurin activity is important for endothelial cell migration, a critical aspect of
angiogenesis. Therefore, the net migratory effect of CsA seen here is the sum of a large
pro-migratory effect of CsA-induced ROS negating the anti-migratory effect of
calcineurin inhibition. This further supports the hypothesis that CsA is affecting
endothelial cell biology in a calcineurin-independent manner. Based on our results and
these studies, current experiments in our laboratory now focus on the involvement of
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calcineurin in fibroblast activation, in which cell migration and adhesion plays an integral
role.

Calcineurin-independent effects of CsA: why Cyclophilin D and the mitochondria?
Despite the importance of calcineurin signaling in endothelial cell biology and
angiogenesis, we have demonstrated the calcineurin inhibitor CsA is able to promote
angiogenesis in a calcineurin-independent manner. Binding of CsA to cyclophilin A
forms a calcineurin-inhibitory complex. In addition to cyclophilin A, CsA also binds to
other cyclophilin family members, resulting in calcineurin-independent effects.
Cyclophilins are a family of proteins with peptidyl-propyl isomerase functions, able to
catalyze the cis-to-trans reaction. Binding of CsA to cyclophilins disrupt their catalytic
function (Nigro et al. 2013). While conserved from yeast to humans, very little is known
about the physiological role of the cyclophilin proteins. Knockout of all cyclophilins in S.
cervasie did not yield any phenotypes (Dolinski et al. 1997), suggesting they may be
important only during pathological or stressed circumstances. In mammals, cyclophilins
have been linked to a number of pathological conditions. Cyclophilin A, in particular, has
been associated with atherosclerosis, cancers, and inflammatory diseases (Nigro et al.
2013). As CsA-induced angiogenesis occurs in a calcineurin-independent manner, , we
theorize that it results from CsA binding to cyclophilin proteins. The most pronounced
and consistent phenotype of pan-cyclophilin inhibition is mediated by cyclophilin D
inhibition. Loss of cyclophilin D activity through pharmacological inhibitors or genetic
deletion results in a ‘stiff’ pore that is resistant to opening in response to stimulus, such as
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cell death signals. Despite being a pan-cyclophilin inhibitor, the use of CsA in multiple
cell types is remarkably specific in its ability to decrease cell death in response to
apoptotic stimulus, underlying the importance of cyclophilin D to cellular homeostasis.

Other cyclophilins: possible contributions to angiogenesis
While cyclophilin D remains the most obvious modulator of CsA pro-proliferative
and migratory effects in endothelial cells, we did not rule out the contribution of other
cyclophilins, or cyclophilin-independent effects of CsA. To this date, no cyclophilinindependent effects of CsA have been described, but the absence of its knowledge does
not necessary rule out its existence. Additionally, while inhibition of cyclophilin D is the
most pronounced cellular effect of pan-cyclophilin inhibitors, CsA still binds to other
cyclophilin family members, the effects of which are unknown.

Cyclophilin A
Cyclophilin A, which binds CsA to form the calcineurin inhibitory complex, is the
most abundant cyclophilin family member, constituting about 0.1-0.6% of total cellular
protein and is characterized with diverse contextual and cell-specific functions. It has
been implicated in pathological conditions such as abdominal aortic aneurysm,
atherosclerosis, diabetes, cancer, neurodegeneration, and several inflammatory conditions
(Nigro et al. 2013). In response to inflammatory stimulus, Ang II, or other stressors,
cyclophilin A can be secreted from macrophages and vascular smooth muscle cells as an
inflammatory cytokine, and can act on vascular smooth muscle cells to increase matrix
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metalloprotease production, promote growth and decrease apoptosis, which contributes to
vascular remodeling (Nigro et al. 2011). Cyclophilin A signaling in endothelial cells has
also been shown to increase adhesion molecules, decrease eNOS, and promote apoptosis
(Nigro et al. 2013). Exogenously administered cyclophilin A has a biphasic effect on
endothelial cell activation where low levels promoted angiogenesis but high levels
decreased endothelial cell viability (Kim et al. 2004).
These studies indicate an important but complex role of cyclophilin A in
pathological vascular conditions. It is unclear whether cyclophilin A has a role in tumor
angiogenesis, despite being strongly linked to cancer progression and metastasis in a cellautonomous manner (Lee & Kim 2010).
Previous studies have shown knockdown of cyclophilin A protects against TNF-α
induced endothelial cell apoptosis (Nigro et al. 2011). While we did show increased cell
numbers with CsA treatment, it was due to increased proliferation without any change in
apoptosis. As a cyclophilin inhibitor, CsA sequesters and inhibits cyclophilin A activity
in endothelial cells, a phenotype which should resemble cyclophilin A deletion mutants.
However, the phenotypes we observed in endothelial cells after treatment with CsA, and
to a lesser extent, NIM811, do not appear to phenocopy cyclophilin A loss described
elsewhere. Therefore, cyclophilin A inhibition by CsA is unlikely to be responsible for
the pro-angiogenic effects of CsA.

Cyclophilin B
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Cyclophilin B is another cyclophilin that is both secreted and retained in the
endoplasmic reticulum, and is important for migration and adhesion of immune cells and
protein folding (Mckeon 1994; Allain et al. 2002). Cyclophilin B expression and activity
has also been found to be aberrant in several tumor types in a cell autonomous manner.
For example, cyclophilin B is overexpressed in 80% of hepatocellular carcinomas and
colon cancers, where it is transcriptionally regulated by HIF-1α and protects against
cisplatin and hypoxia-induced apoptosis. In the same study, cyclophilin B was also
shown to regulate HIF-1α associated angiogenesis by inducing VEGF production (Kim et
al. 2011). Furthermore, cyclophilin B was also found to support glioblastoma multiform
tumor cell survival by stabilizing the oncogenic proteins myc and p53, likely through its
chaperone activity (Choi et al. 2014). In harsh oxidative conditions, cyclophilin B may
also indirectly protect against oxidative damage by stabilizing myc, leading to increased
transcription of UCP2, a mitochondrial uncoupling protein (Choi et al. 2014). These
studies indicate a broad potential role of cyclophilin B in a cancer cell-autonomous
manner. In the vasculature, however, cyclophilin B is not known to be expressed or have
a physiological role. While cyclophilin B has been shown to be expressed in endothelial
cells after shock wave stress (Holfeld et al. 2014), it has not been otherwise described to
be present or functional in endothelial cells or angiogenesis.
Inhibition of cyclophilin B by CsA in tumor cells could potentially decrease
hypoxia-induced HIF-1α responses such as angiogenesis and also destabilize mutant p53
and oncogenic c-myc, which could lead to decreased protection against oxidative stress.
This may explain the increased ROS-dependent tumor angiogenesis in vivo seen in the
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setting of CsA treatment. However, it does not account for the effects of CsA on
endothelial cells in vitro, which are untransformed primary cells cultured in normoxic
conditions.

Cyclophilins C & E
Also discovered as a binding partner to cyclosporin A, cyclophilin C is expressed
at much lower levels than cyclophilin A and has lower binding affinity to CsA than either
cyclophilin A or B (Schneider et al. 1994). Little is known about the physiological
function of cyclophilin C. Similarly, cyclophilin E, a nuclear and RNA binding
cyclophilin, was recently described to bind to influenza viral proteins to retard their life
cycle but is otherwise poorly understood (Wang et al. 2011). These proteins have not
been described to be important in tumorigenesis, and none have been described to
participate in angiogenesis. The outcomes of inhibition of these cyclophilins by CsA are
unclear.

Unbiased screen vs. candidate approach for CsA interactors
While other cyclophilin family members, in particular, cyclophilin A, may be
involved in pathological endothelial cell biology, cyclophilin D still remains the most
attractive candidate to explain the proliferative and migratory phenotype seen with CsA
treatment. Nevertheless, future studies are needed to definitively rule out the contribution
of other CsA interactors, either cyclophilins or other molecules, to the pro-proliferative
phenotype observed with CsA.
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In this study, I have taken a candidate approach where I identified a likely target
protein through a literature analysis. Subsequent testing of the phenotypical output such
as the mitochondrial ROS was consistent with my hypothesis. To fully confirm this
hypothesis, genetic manipulation should be used.
Transgenic mice lacking cyclophilin D are viable and fertile and are protected
from ischemia-reperfusion injury in vivo (Nakagawa et al. 2005) but display increased
anxiety and brain white adipose tissue (Luvisetto et al. 2008), indicating a role for
cyclophilin D in mitochondria-associated cell death and metabolism. Primary endothelial
cells isolated from mice lacking cyclophilin D is expected to behave similarly to wildtype endothelial cells treated with CsA or NIM811, which inhibits cyclophilin D. In fact,
mitochondria isolated from cyclophilin D null cells have MPTP that are resistant to
calcium-induced opening, in a manner similar to inhibition of cyclophilin D by CsA
(Nakagawa et al. 2005). Given my hypothesis, I expect endothelial cells isolated from
cyclophilin D null mice to have increased proliferation and migration in vitro compared
to wild-type endothelial cells, similar to CsA treatment. Additionally, cyclophilin D null
endothelial cells are expected to display increased mitochondrial membrane potential and
mitochondrial ROS production compared to wild-type endothelial cells. Xenografted
tumors on cyclophilin D null mice are expected to have increased tumor growth and
angiogenesis. To test whether endothelial cell cyclophilin D is important for CsA-induced
tumor angiogenesis in vivo, one can conditionally delete cyclophilin D specifically in
endothelial cells, rather than complete elimination of cyclophilin in all host cells.
Breeding the transgenic VE-cadherin Cre recombinase mouse with the transgenic
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cyclophilin DloxP/loxP mouse (Schinzel et al. 2005) should yield transgenic mice with
deletion of cyclophilin D only in endothelial cells. If endothelial cells are responsible for
tumor angiogenesis and growth in CsA-treated animals, then loss of cyclophilin D
specifically in the endothelial cells should mimic CsA treatment in wild-type animals
when subjected to a tumor model. Any deviations from these expected outcomes, either
partially or completely, would indicate that CsA is either not binding to cyclophilin D or
is affecting multiple pathways in addition to cyclophilin D to result in pro-angiogenic
effects.
If cyclophilin D loss does not phenotypically mimic CsA treatment in vitro and in
vivo on endothelial cells and tumor growth, it is possible that CsA is exerting an effect
through another cyclophilin protein, or a yet unidentified non-cyclophilin pathway. If we
assume CsA is exerting its effects through another cyclophilin protein, then systematic
siRNA knockdown of all 7 mammalian cyclophilin genes (16 unique proteins) should
identify the CsA interactor(s) responsible for increased proliferation, migration, and
mitochondrial ROS in endothelial cells.
To more broadly understand the effects of CsA and identify potential interacting
proteins responsible for the effects observed, including non-cyclophilin proteins, it would
be pertinent to use an unbiased screen. Unlike a targeted candidate approach, an unbiased
screen systematically manipulates a much larger number of potential targets. Using a
broader approach, such as an unbiased library of RNA interference (RNAi), to
knockdown single genes in endothelial cells with or without CsA treatment, would allow
for identification of genes that are immediately downstream of CsA-induced readout such
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as cell proliferation and ROS generation. In this case, RNAi knockdown of the putative
CsA interactor would then negate the pro-proliferative and pro-ROS effects of CsA
whereas RNAi knockdown of unrelated transcripts should not affect CsA’s effects on
proliferation and ROS (when compared to vehicle-treated). Potential targets would then
be identified and direct binding to CsA would be confirmed through immunoprecipitation.
Further characterization studies using FK506 and NIM811 would be expected to agree
with existing experiments. The RNAi approach has been used extensively but is not
without flaws as RNA interference only partially suppresses target gene expression and
may have off-target effects on unrelated transcripts.
A more recent screen uses the newly developed clustered regularly interspaced
short palindromic repeat (CRISPR)-Cas system, which was conceived from a RNA-based
prokaryotic immune system (Wang et al. 2014). In this system, lentiviral vectors carry
small segments of RNA, corresponding to the gene of interest, engineered as single-guide
RNA (sgRNA), and direct Cas nucleases (usually Cas9, also expressed from the same
viral vector) to cause double-stranded cleavage of matching targeted genomic DNA
sequence (Shalem et al. 2014; Zhou et al. 2014; Wang et al. 2014). This allows for
specific genomic deletion of a target gene. When used in combination with a library,
either an unbiased or focused library, it is possible to individually delete target genes and
then perform functional studies after subjecting to experimental treatments. Using this
technology, one can identify proteins that either interact with CsA or are downstream of
CsA interactors by screening for loss of CsA-induced cell proliferation and elevated ROS
in cells. The advantage of the CRISPR-Cas9 screening system over the RNAi screening
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system is that suppression of the target gene is complete due to its excision, whereas the
RNAi system only partially suppress the target gene. A limitation of both systems is that
in addition to identifying direct CsA interactors, they would also identify genes
downstream of those proteins. Therefore, once target genes are identified, direct CsA
interaction would need to be confirmed with immunoprecipitation studies.
Genetic screens, either the RNAi or CRISPR-Cas9 system, would provide an
unbiased means to identify CsA interactor(s) or confirm the current selected candidate
that is/are responsible for the pro-angiogenic effects seen. Future studies using either one
of these systems would greatly strength my hypothesis and may provide additional targets
to understanding the tumorigenic effects of CsA.

Relationship between ROS and CsA

Mitochondria and ROS: evidence for the actions of CsA
Treatment with CsA or its non-immunosuppressive analog NIM811 results in
increased mitochondrial ROS and cell proliferation, which was abolished with
antioxidant co-treatment. Moderate increases in ROS have been shown to promote
mitogenic signaling pathways (Thannickal & Fanburg 2000), consistent with our data.
CsA is also known to inhibit calcium-induced irreversible MPTP opening in the
setting of mitophagy or cell death. Inhibition of cyclophilin D during cell death raises the
stimulus threshold required for the collapse of the mitochondrial membrane potential,
ultimately decreasing apoptosis (Halestrap 2009; Kim et al. 2003). This property of CsA
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is currently exploited to manipulate ischemia-reperfusion injury in cardiomyocytes
(Halestrap & Richardson 2014).
In the absence of cell death signals, treatment with CsA increases mitochondrial
ROS production, in agreement with previous studies (Krauskopf et al. 2005; RedondoHorcajo et al. 2010; Akool et al. 2012). This process originates from an alternative
mitochondrial pore state termed ‘physiological flickering’. In this reversible state, the
transient opening of the MPTP is brief, isolated, stochastic, reversible, and does not result
in membrane depolarization or cell death (Wang et al. 2012). Instead, individual
reversible MPTP opening events are thought to act as a pressure release valve to regulate
membrane potential, ultimately affecting mitochondria metabolism and the mitochondriacytoplasm crosstalk (Wang et al. 2012). Changes in mitochondrial membrane potential
can alter the production of ROS (Korshunov et al. 1997), a byproduct of the electron
transport chain during the process of oxidative phosphorylation. We hypothesize that
inhibition of the reversible MPTP opening by CsA increases mitochondrial membrane
potential, leading to increased ROS production. In order to fully appreciate the effects of
CsA on mitochondrial biology, a thorough summary of mitochondrial bioenergetics
leading to ROS production will be presented in the following section, followed by a
discussion on the effects with CsA on this system.

Oxidative-phosphylorative pathway
The mitochondrion is a major source of reactive oxygen species, produced as a
byproduct of the electron transport chain. The electron transport chain is the final portion
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of cellular respiration in which high energy electrons from energy-rich substrates such as
NADH and FADH2 are transferred, in a sequential and stepwise manner, to various
energy carriers along the chain, until it becomes accepted by oxygen to form water. The
fall of electrons down its energy gradient results in the generation of an electrochemical
gradient across the mitochondria inner membrane which serves as the driving force for
the regeneration of ATP. Comprehension of mitochondrial bioenergetics, especially
oxidative phosphorylation, is critical to understanding how regulating MPTP activity can
affect mitochondrial reactive oxygen species production.
The mitochondrion is separated into two compartments (the intermembrane space
and the matrix) by two membranes (outer and inner mitochondrial membrane) through
which electrochemical gradients can be generated and exploited for energy production.
The outer mitochondrial membrane defines the mitochondria as an organelle. In between
the outer mitochondrial membrane and the inner mitochondrial membrane is the
intermembrane space, which has a similar electrolyte and small solute composition as the
cytosol. The inner mitochondrial membrane is highly convoluted and folded, thereby
presenting a large surface area through which metabolic reactions can take place. The
inner mitochondrial membrane encloses the mitochondria matrix, which is highly basic
and negatively-charged (Rich & Marechal 2010).
In eukaryotes, the electron transport chain is composed of five major complexes
and two electron carriers. High energy substrates such as NADH (or FADH2) are
generated in the mitochondrial matrix by the citric acid cycle. NADH in the matrix is
taken up by complex I (also known as the NADH dehydrogenase), a large flavoprotein
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complex which contains iron sulfur redox centers and spans the inner mitochondrial
membrane. Complex I then acts to remove two electrons from NADH and deposits them
onto Coenzyme Q (CoQ), reducing the oxidized CoQ (ubiquinone) to reduced CoQ
(ubiquinol). This electron transfer from NADH to CoQ also drives the movement of 4
protons (H+) from the mitochondrial matrix out into the intermembrane space,
contributing to the electrochemical gradient. CoQ is a lipid-soluble mobile electron
carrier that can then move from the membrane-spanning complex I to complex III (Rich
& Marechal 2010).
Complex II (also known as succinate dehydrogenase) also supplies reduced CoQ
to Complex III, but does so by converting succinate to fumarate, using FADH2 as the
high energy intermediate. Unlike complex I, III, IV, or V, complex II does not pump H+
(Rich & Marechal 2010).
Reduced CoQ generated from Complex I (or II) is taken up by Complex III (also
known as cytochrome c reductase) it is bound to cytochrome b and the electrons are
transferred onto cytochrome c at the Rieske 2Fe/2S center. One electron from the reduced
CoQ is placed onto cytochrome c during each cycle while the other electron is passed
from cyt.bL onto cyt.bH to regenerate the oxidized CoQ in a process called the Q cycle.
While the Q cycle does not affect the final output of complex III, where two electrons are
transferred from one CoQ onto two cytochrome c (each cytochrome c can only carry one
electron), the Q cycle is a potential source of ROS production and will be addressed later.
For each CoQ that is oxidized, two H+ are pumped from the mitochondrial matrix into the
intermembrane space (Rich & Marechal 2010).
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Cytochrome c is a mobile electron carrier in the intermembrane space. Each
reduced cytochrome c carries one electron from Complex III to Complex IV (also known
as cytochrome c oxidase) where it is passed through a sequence of heme and metal
groups, generating energy to pump 2 H+ into the intermembrane space. The terminal
electron acceptor in Complex IV is O2, which requires four electrons to become reduced
to two molecules of water (4 H+ are added to maintain the charge neutrality) (Rich &
Marechal 2010). While cytochrome c participates primarily in oxidative phosphorylation
as an electron carrier, it also has a pro-apoptotic role when released into the cytosol by
facilitating the formation of an apoptosome (Tait & Green 2010).
Complex V is the final unit in the oxidative phosphylorative pathway. More
commonly known as the ATP FO/F1 synthetase, complex V does not move electrons, but
instead it utilizes the proton gradient created by Complex I, III, and IV to regenerate ATP
from ADP. This large structure is composed of two portions: FO-a ring shaped complex
containing the ATP synthase FO subunit 6 (encoded by ATP6) which forms a proton
channel, and F1-a central stalk ending in a ball complex. The FO ring is embedded in the
inner membrane and through its subunit 6/ATP6, encompasses a channel to allow for the
passage of H+ to move from the intermembrane space into the matrix down its gradient.
The movement of H+ causes the FO ring to rotate, which causes rotation of the central
stalk (part of the F1 portion). The matrix end of the central stalk has a small hook and is
connected to the ball-shaped complex of the F1 portion. Rotation of the central stalk (due
to proton movement through the FO ring) causes the hook at the end of the stalk to disturb
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the ball-shaped complex in the F1 portion, providing energy for the conformational
changes leading to ATP synthesis (Rich & Marechal 2010).

Source of ROS generation in the mitochondria
The electron transport chain is very tightly coupled and the electrical efficiency of
each complex in individual mitochondria must be perfectly balanced to the other
complexes. Deviations or changes in any of the complexes can short the electrical circuit
across the inner membrane. Therefore, the genes transcribing critical electrical
components in these complexes must be inherited together. Assorted inheritance of these
genes through sexual recombination would off-set the coupling coefficiency of these
complexes and the ensuing results would be disastrous for the organism. Therefore, the
mitochondrial genome (mtDNA), which is vertically inherited from mother to child,
encodes for the core electrical components of Complex I, III, IV, and V, effectively
avoiding the combination of incompatible circuit elements (Wallace 2005).
The inheritance pattern of the core mitochondrial complexes demonstrates the
importance of maintaining the electrochemical gradient in the mitochondria. Alterations
in the gradient not only affect ATP generation, but also alter the efficiency of the electron
movement in the electron transport chain. The movement of electrons through the
electron transport chain is tightly regulated and controlled, but as they are high energy,
unstable atomic particles, electrons may occasionally react directly with oxygen instead
of passing on the respiratory chain. The addition of an electron directly to O2 results in
the formation of superoxide anion (O2∙-), a type of reactive oxygen species, which can be
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converted to other reactive oxygen species by various chemical reactions. Even under
optimal conditions, there is always a small electron leak from the electron transport chain
which results in ROS formation (Adam-Vizi & Chinopoulos 2006). Under nonphysiologic (excessively low or high) metabolic states, the electron leak may become
greater, leading to greater ROS production (Selivanov et al. 2011).
The main sites of electron leak are at complex I and complex III. When succinate
is in abundance, it leads to a high pool of reduced CoQ, which can drive the reverse
electron transport in Complex I (Lambert & Brand 2009). The mobile electrons in the
accumulated reduced CoQ proteins in the iron sulfur centers and FMN in Complex I can
react with O2, leading to superoxide generation. Superoxide production from complex I
has been implicated in the pathogenesis of Parkinson’s disease, fatal infantile lactic
acidosis, and Leigh disease (Hirst et al. 2008). ROS produced from Complex I appears to
be delivered exclusively into the mitochondrial matrix (Lambert & Brand 2009). Another
site of ROS production on the electron transport chain is Complex III. Like Complex I,
Complex III can also produce ROS during reverse electron transport, although the rate of
ROS production in those conditions is thought to be relatively low in comparison
(Lambert & Brand 2009). Inhibition of the Q-cycle (which recycles oxidized CoQ within
Complex III) between cyt bH and Qi site by antimycin causes the formation of the
unstable semiquinone at the Q0 site, which readily transfers its single electron to O2 (Cape
et al. 2007). ROS produced from Complex III is delivered into both the mitochondrial
matrix and the intermembrane space (Lambert & Brand 2009).
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The addition of electrons directly to oxygen produces superoxide, a highly
reactive non-diffusible reactive oxygen species. Although superoxide is charged and
incapable of diffusing across membranes, it is converted to hydrogen peroxide by either
manganese superoxide dismutase (in the mitochondrial matrix) or copper zinc superoxide
dismutase (in the intermembrane space). The resulting hydrogen peroxide is more stable
and freely diffusible, and is able to leave the mitochondria to enter the cytoplasm, and
further into extracellular space, affecting redox metabolism to beyond the mitochondria
(Giorgio et al. 2007).

Factors affecting ROS production in the mitochondria: effect of membrane potential
While particular uncoupling drugs can selectively affect ROS production
specifically in either Complex I or III, the entire electron transport chain is sensitive to
changes in the mitochondrial electrochemical gradient. The electrochemical gradient is
the combined effect of the pH gradient and the mitochondrial membrane potential (Δψ).
Changes in either mitochondrial matrix pH (Lambert & Brand 2004) or Δψ (Selivanov et
al. 2011; Nicholls 2004) have been shown to affect the mitochondrial ROS production.
When the mitochondrial membrane potential increases (denoted by a more
hyperpolarized, or negative Δψ), the mitochondrial matrix is more reduced, making it
energetically more difficult for the negatively charged electrons to move to the matrixside of the complexes. This result in stalling of the electron transport chain, and the
reduction of alternative acceptors, such as O2, become more favorable. Therefore, the
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mitochondrial membrane potential is tightly controlled to optimize ATP generation and
minimize ROS generation.

MPTP: regulation of mitochondrial membrane potential
The MPTP was historically discovered in relation to its participation in cell death
(Crompton 1999). However, the MPTP has also been observed to be active in nonapoptotic conditions. In the absence of continued calcium stimulation, the MPTP can
stochastically flicker open and close (Wang et al. 2008). The function of these stochastic
openings has not been clearly demonstrated, but is thought to regulate mitochondriacytosolic crosstalk or mitochondrial metabolism (Wang et al. 2012). One of the
immediate effects of MPTP flickering is that the transient opening between the
mitochondrial matrix and cytosol allows for a brief movement of charged solutes
(<300Da) between these two compartments, causing a dip in the mitochondrial
membrane potential (Wang et al. 2012; Brenner & Moulin 2012). As fluctuations in the
mitochondrial membrane potential can modulate ATP generation and ROS production,
the transient opening of the MPTP is thought be a regulatory means for maintaining the
mitochondrial membrane potential at approximately -180mV (Huser & Blatter 1999;
Wang et al. 2012). These transient flickering of the MPTP has also been proposed to
regulate mitochondrial matrix pH (Ichas & Mazat 1998).
Like the irreversible mode of opening, this transient form of MPTP opening is
also sensitive to inhibition by CsA. Similarly, CsA treatment does not completely render
the MPTP refractory from opening, but instead it raises the stimulus threshold required
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for it to open. Considering the transient MPTP flickering may be responsible for
maintaining the mitochondrial membrane potential by acting as a release valve,
decreasing pore opening through treatment with CsA would theoretically lead to
increased mitochondrial membrane potential, which has been independently established
to increase ROS production in the electron transport chain (Korshunov et al. 1997; Hirst
et al. 2008; Miwa & Brand 2003).
Our data is consistent with this hypothesis and shows CsA treatment potently
increases mitochondrial membrane potential, demonstrating that it is a feasible means
through which CsA could increase mitochondrial ROS. One caveat of our experiments is
that it only provides an associative link between the increased mitochondrial membrane
potential and mitochondrial ROS production in the setting of CsA treatment, and future
studies are need to show a causal effect. One potential means of addressing the issue of
mitochondrial ROS is the genetic overexpression of mitochondrial antioxidants such as
manganese dismutase or copper zinc dismutase, which would neutralize any elevated
mitochondrial ROS and should abolish CsA-induced effects. Additionally, cells isolated
from cyclophilin D null mice should behave similarly to CsA treated wild-type cells with
a basal increase in mitochondrial membrane potential and increased mitochondrial ROS
production.

Global effector molecule: CsA side effects and ROS signaling
While we show that CsA-induced ROS in endothelial cells promotes cell
proliferation, other groups have found it to confer toxicity (Redondo-Horcajo et al. 2010).
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The diverse effects associated with CsA-induced ROS may be due to the promiscuous
nature of ROS signaling, especially in different cell types. Moreover, the level of ROS
may be dependent on CsA concentrations.
Dose-dependent induction of ROS by CsA would have broad clinical significance,
as variable tissue accumulation of CsA in combination with cell-specific responses to
CsA-induced ROS may further explain the numerous multi-organ side effects seen with
CsA treatment. Indeed, CsA-induced ROS can contribute to CsA-associated
nephrotoxicity. In vivo studies have found CsA treatment increases the glomerular
synthesis of ROS, thromboxane, and lipid peroxidation products in the kidney (Parra Cid
et al. 2003). Furthermore, increased ROS has been linked to hypertension pathogenesis,
as superoxide can react with nitric oxide to generate peroxynitrate, decreasing the pool of
the vasodilator nitric oxide (Yung et al. 2006). Additionally ROS has been identified as a
mediator between CsA and the activation of the renal-angiotensin system in the setting of
transplant associated hypertension (Nishiyama et al. 2003). Taken together, CsA-induced
ROS may be a viable target for the development of therapies to mitigate adverse effects
of CsA use.

CsA effects in endothelial cells: aggregation of calcineurin and ROS signaling.
As is evident from the literature and our studies, CsA treatment has multiple
effects. This stems partly from the cell-specific role of calcineurin and the dosedependent effects of ROS. Depending on the scale of inhibition or activation of these
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pathways, the final effect of CsA on cell biology is variable. In endothelial cells
specifically, CsA negatively regulates the VEGF-calcineurin axis, where maximal

Fig. 4.2. Model of signaling pathways affected by CsA in relation to endothelial
cell proliferation. As CsA levels increase moderately, it exerts both a proproliferative effect through moderately elevated ROS and a slight anti-angiogenic
effect through calcineurin inhibition, with an overall pro-growth effect. At high levels,
CsA induce toxic levels of ROS and maximally inhibit calcineurin, resulting in
decreased endothelial cell numbers.
calcineurin inhibition blocks angiogenesis (Hernández et al. 2001). Furthermore, CsAinduced ROS has a gradient effect on proliferation and apoptosis. It is important to
recognize that CsA treatment in endothelial cells has a dose-dependent effect on both the
calcineurin and ROS signaling pathways, which results in a bell-shaped effect on
proliferation and cell numbers (Fig. 4.2.). This model allows for the pro-proliferative
outcome seen in our studies, but also explains the cytotoxic effects seen at other CsA
doses.
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Clinical Implications

Antioxidant therapy
We are the first to demonstrate that antioxidant therapy decreases CsA-induced
tumor growth in an in vivo model. This result raises obvious clinical implication of using
antioxidants therapeutically for patients on CsA containing drug regiments. Antioxidants
are a class of drugs with a large therapeutic window, mild side effects, few major drug
interactions, and can be obtained over-the-counter as health supplements. While large
clinical trials have failed to show the efficacy of antioxidants for preventing
cardiovascular disease (Vivekananthan et al. 2003), it nonetheless has been shown to be a
safe and well tolerated drug. More studies are necessary to determine the exact
antioxidant, optimal dose, and its effect on outcome.
One potential point of concern for antioxidant treatment in the setting of cancer is
highlighted by a recent study which showed increased mortality and decreased survival in
a mouse model of cancer with antioxidant treatment. In this study, N-acetyl cysteine
(NAC) and vitamin E treatment increased progression of B-raf and K-ras induced lung
tumors and reduced the survival of these tumor-bearing mice compared to vehicle treated
(Sayin et al. 2014). This was thought to be due to disruption of the ROS-p53 axis by
antioxidants, which would otherwise limit tumor growth. It is important to take into
consideration that the role of reactive oxygen species, and therefore, antioxidant
treatment is complex and may have adverse unintended effects.
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NAC used in our studies is a FDA approved antioxidant, used clinically as an
antidote for acetaminophen overdose (Atkuri et al. 2007). Other antioxidants such as
Vitamin C and E may be more applicable for long term use. Given the potential protumor risk associated with NAC and vitamin E (Sayin et al. 2014), mitochondrially
targeted antioxidants may be more specific for targeting mitochondrially generated ROS.
A diet high in antioxidant-rich foods such as fruit and vegetable are recommended for a
healthy lifestyle, and may be even more important for transplant patients.
Surgical excision is the mainstay for cutaneous squamous cell carcinoma, but
chemoradiation is often utilized in setting of transplant-associated skin cancers. Many
current chemotherapeutic drugs have high toxicity, and some are also carcinogenic or
mutagenic. Therefore, in transplant patients, it is important to weigh the potential dangers
of antioxidant treatment with the risks of cancer, and also compare its benefits and
toxicities with that of the current standard treatments.

Prophylactic use:
Transplant associated cancers typically occurs years to decades after the onset of
immunosuppressive treatment. This variable latent period opens up the possibility of
taking preventive measures to decrease the oncogenic risk. Drugs used for prophylaxis
must balance the risks and benefits of use, especially for long term use for an adverse
event which materializes in only 50% of patients (Euvrard et al. 2003). Systemic retinoid
have shown efficacy as chemopreventative treatments for decreasing the incidence of
squamous cell carcinoma in transplant patients (Lien et al. 2012; Bettoli et al. 2013), but
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incurs multiple side effects including a high risk of teratogenicity. While antioxidant
usage generally results in less severe side effects than systemic retinoid, more studies are
needed to determine its safety, especially in the light of potential tumor-promoting
properties discussed earlier. In our experiments, we show that antioxidant treatment in a
mouse model of melanoma decreases tumor growth, but the ideal goal of prophylactic
treatment is to decrease both the incidence of disease in addition to disease burden.
Future studies using spontaneous animal models of skin cancer such as the DMBA-TPA
chemical carcinogenesis model or UV induced SCC model would be useful to further
characterize the effect antioxidant prophylaxis on CsA-associated tumors.

Therapeutic use:
In addition to preventative use, antioxidants may also be useful as therapeutic
treatment, in combination with standard therapy for transplant associated cancers.
Transplant associated skin cancers are much more aggressive and metastatic than their
spontaneous counterparts (Euvrard et al. 2003). In the case of spontaneous squamous and
basal cell carcinomas, the tumors remain relatively indolent for long periods of time, and
carries excellent prognosis if surgically removed. In the case of CsA-associated skin
cancers, however, invasion occurs much faster, and multi-organ metastasis is not
uncommon. Moreover, prognosis for CsA-associated skin cancers is much poorer than
spontaneous skin cancers and current treatments recommended for skin cancers, surgical
and occasional chemoradiation therapies (Jennings & Schmults 2010) are not always
sufficient. Therefore, there exists a niche for better treatment options. Here we show
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CsA-associated tumor growth can be slowed with antioxidant treatment, suggesting
antioxidants may be utilized as adjuvant therapy, in addition to current standard-of-care,
to treat transplant associated cancers.

Anti-angiogenic therapy to target CsA-associated cancers
In our study, we have discerned that CsA treatment increases tumor angiogenesis
through increased ROS, and antioxidants may be both a prophylactic and therapeutic
treatment option. Alternatively, there are many existing anti-angiogenic therapies that
may have a beneficial application for transplant associated cancers. Although
invasiveness in skin cancers is associated with greater vascularization (Staibano et al.
1996), anti-angiogenic therapies are not routinely used to treat skin cancers. Antiangiogenic therapies for other cancer types have shown mixed results (Bergers &
Hanahan 2008), reflecting the complexity of the tumor vessel contribution to both disease
progression and treatment efficacy. Nonetheless, anti-angiogenic drugs are FDA
approved and well characterized, and may offer treatment benefit for transplant
associated skin cancers.

Anti-angiogenic target: calcineurin pathway
One of the questions leading to this study was the paradox of how CsA, a
calcineurin inhibitor, increased tumor growth. According to the previously defined role of
calcineurin in endothelial cells, inhibition of calcineurin interferes with VEGF signaling
in endothelial cells, resulting in decreased tumor angiogenesis and tumor growth in vivo
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(Baek et al. 2009). The development of calcineurin inhibitors as anti-angiogenic drugs
was hampered by the clinical experience with CsA usage, which clearly demonstrates
pro-tumor activities. As we have dissected out the angiogenic component of CsA’s protumorigenic effect to be calcineurin-independent, it allows calcineurin inhibition to be
once again considered as an anti-angiogenic target. There are a number of calcineurin
inhibitors, both small molecule drugs and endogenous inhibitors, which can be employed.
CsA is a poor choice as it promotes angiogenesis through an independent mechanism.
From our studies, it would appear FK506 is also an inferior choice as it did not decrease
tumor growth compared to control treatment. Pimecrolimus, a macrolide antibiotic
similar to FK506 remains a possibility, but needs to be investigated. While not clinically
used, other molecules such as DSCR1, autoinhibitory domain (AID) (Perrino 1999),
cabin-1/cain (Sun et al. 1998), AKAP79 (Kashishian et al. 1998), and the A238L protein
from the African swine virus (Miskin 1998) are known to inhibit calcineurin directly.
Additionally, other molecules such as Dyrk-1A (Arron et al. 2006; Gwack et al. 2006)
can target NFAT phosphorylation, the main effector of calcineurin activation, to block
calcineurin activity further downstream. VIVIT, a small molecule developed based on the
NFAT docking sequence, inhibits the calcineurin/NFAT interaction (Yu et al. 2007), and
is an attractive candidate to selectively inhibit calcineurin activity in endothelial cells.
Significant work, however, is needed for the development of any of these small molecule
inhibitors to clinical use in order to address the issues of permeability, stability, and
pharmacokinetics. Nonetheless, they remain promising novel therapeutic agents for
selective inhibition of calcineurin-induced tumor angiogenesis.
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CHAPTER 5: MATERIALS AND METHODS

Primary endothelial cell isolation
Primary lung endothelial cells were isolated from 3-4 week old adult mice.
Briefly, whole lungs were minced and digested in Hanks Balanced Salt Solution (HBSS;
Invitrogen) containing 10mg/mL type II collagenase (Worthington) and 20µg/mL DNase
I (Sigma-Aldrich) for 30-45 minutes at 37°C with shaking. The collagenase was
quenched with equivolume FBS, then filtered through progressively smaller cell strainers
(100 and 40 μm) and centrifuged. Red blood cells were lysed with ACK Lysing Buffer
(Invitrogen), then centrifuged and washed once in HBSS with 0.5% BSA (Invitrogen).
Cells were incubated first with mouse Fc blocking reagent (Miltenyi Biotech) for 5
minutes on ice, then anti-CD31 biotinylated antibodies (1:100; ebiosciences, Clone 390)
for 30 minutes at 4°C, rotating, washed once in MACs buffer, and then resuspended in
MACs buffer with anti-biotin microbeads (Miltenyi Biotech) for 15 minutes before being
applied to a magnetic column (Miltenyi Biotech). CD31 positive cells were seeded on 0.1%
gelatin coated plates and cultured in endothelial cell media, Advanced DMEM
(Invitrogen) supplemented with 15% FBS, 2mM glutamine, 100units/mL penicillin, and
100µg/mL streptomycin, 25mM Hepes (Invitrogen), 100µg/mL heparin (Sigma-Aldrich),
and 100µg/mL ECGS (Biomedical Technologies, Stoughton MA). After 7 days, a second
CD31 selection was performed. Endothelial cell purity was determined by
immunostaining with anti-CD31 rat antibody (BD Pharmingen).
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Reagents
NIM811 was a gift from Novartis. CsA and FK506 (Sigma-Aldrich) for in vitro
experiments were reconstituted in ethanol at 8.3mM for a stock solution and further
diluted in sterile water for working solutions and used at 0.25µM and 0.1µM respectively,
unless indicated otherwise. N-acetyl cysteine (Sigma-Aldrich) was reconstituted in sterile
water and used at 5mM for in vitro experiments or 40mM for in vivo treatment.
Mn(III)tetrakis(4-benzoic acid)porphyrin Chloride (Millipore) was diluted in sterile water
and used at 10µM. Angiotensin II (Sigma-Aldrich) was reconstituted in sterile water and
used at 100nM.

Animals and Tumor Studies
WT C57Bl/6 mice were from The Jackson Laboratory. Dscr1 transgenic mice
with a third copy of Dscr1 targeted into the hypoxanthine phosphor-ribosyltransferase
locus were generated as previously described (Baek et al., 2009). Calcineurin Bf/f mice
with loxP sites flanking the Calcineurin B gene were originally from The Jackson
Laboratory. For CsA or FK506 drug treatments, mice were orally gavaged daily with
10mg/kg of CsA oral solution USP modified (Hospital of University of Pennsylvania
(HUP) Pharmacy) diluted in peanut oil or 0.15mg/kg of FK506 (HUP Pharmacy) diluted
in simple syrup, for the duration of the experiment. Mice were 8-12 weeks old. All
animal experiments were performed according to protocols approved by the University of
Pennsylvania institutional animal care and use committee.
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Chemical carcinogenesis skin tumor model
Mice were treated with a single cutaneous application of 25µg of 7,12dimethylbenz(a)anthracene (DMBA; Sigma-Aldrich) in 200µL of acetone on the shaved
dorsal surface, followed by twice weekly cutaneous applications of 12.5µg 12-Otetradecanoylphorbol-13-acetate (TPA; Sigma-Aldrich) in 200µL of acetone for 40 weeks.
Tumor incidence was palpated by hand weekly.

Melanoma tumor model
B16-F10 melanoma cells (ATCC) were cultured in DMEM (Invitrogen)
containing 10% FBS, 2mM glutamine, 100units/mL penicillin, and 100µg/mL
streptomycin. For injection, cells were trypsinized, washed in PBS, counted and
resuspended in sterile PBS. Each mouse received 3x105 cells subcutaneously on the
dorsal side. Tumor growth was measured by calipers daily. Mice were euthanized if they
became moribund or tumors became ulcerated prior to experimental endpoint.

Immunofluorescence and CD31 quantification
Tumors were harvest from mice after euthanasia and frozen in OCT freezing
medium (Tissue-Tek), then sectioned for staining. Slides were fixed and permeabilized in
ice cold acetone for ten minutes, blocked with 5% normal goat serum and 1% BSA. Then
the slides were incubated overnight at 4° C with rat anti-mouse CD31 antibody (1:50, BD
Biosciences). Secondary antibody was Alexa 594 goat anti-rat (1:2000, Invitrogen) and
nuclei were identified with Hoechst33342 (1:1000, Invitrogen). Five random 10X
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magnification pictures were taken of each slide. Images were taken at RT with a 10× or
20× magnification objective lens and with a digital camera AxioCAM HRc (Zeiss,
Thornwood, CT) mounted on Zeiss Imager M1 Axio using Zeiss AxioVision Acquisition
software (version 4.5). The area of CD31+ structures, visible lumens, total vessels, and
vessels >100µm were counted. Vessel structures for all tumors within a treatment group
were averaged to determine average and standard deviation.

Miles Assay of vessel permeability
200µL of 0.5% sterile solution of Evans blue in PBS was injected tail vein into
tumor-bearing mice and allowed to distribute into tissues for 30 minutes, followed by
animal sacrificing and tumor removal. Excised tumors were weighed and 500µL
formamide was added to each sample and incubated at 55ºC for 24-48 hours to extract the
Evans blue. The tumor/formamide mixture was pelleted and the dye concentration in the
supernatant was measured with absorbance at 610nm and calculated as ng Evans blue
extravasated per mg tissue.

Proliferation and cell growth
Endothelial cells were plated in triplicates at 5 x 103 cells per well in 0.1% gelatin
coated 24-well tissue culture plates. Cells were counted daily or every other day. Media
was changed every 3 days.

BrdU incorporation
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2.5 x 103 endothelial cells were plated onto 0.1% gelatin coated glass coverslips.
10µM BrdU (BD Biosciences) was added to cells for 1.5 hours at 37°C. Cells were fixed
with 4% paraformaldehyde (PFA) for 15 minutes, permeabilized with 0.1% TBST for 15
minutes, and DNA was denatured with 2N HCL for 30 min. Endothelial cells were
stained with anti-BrdU mouse antibody (1:50, Dako) for 1 hour at room temperature.
Secondary antibody was Alexa 594 goat anti-rat (1:2000, Invitrogen) and nuclei were
identified with Hoechst33342 (1:1000, Invitrogen). Seven random 10X magnification
pictures were taken of each slide and BrdU positive cells and total cell number were
counted.

Tunel apoptosis assay
To measure apoptosis, in situ terminal deoxynucleotidyltransferase-mediated
dUTP nick end labeling (TUNEL) labeling was performed using the DeadEnd
Fluorometric TUNEL System (Promega, Madison, WI) according to manufacturer's
instructions. Briefly, endothelial cells were washed with PBS and trypsinized, then fixed
with 4% PFA for 20 minutes on ice. Cells were permeabilized by 70% EtOH for 4 hours
at -20C, washed with PBS, then incubated in equilibration buffer for 5 minutes. Cells
were then incubated with TdT reaction mix for 60 minutes, washed, and resuspended in
20mM EDTA to stop the reaction. Cells were then incubated with 5µg/mL propidium
iodide (Sigma-Aldrich) with 1mg/mL RNase for 20 minutes at room temperature. Flow
cytometry was performed on a FACS Canto flow cytometer (BD Biosciences) and
analyzed with FlowJo Software (TreeStar, Ashland, OR).
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Migration assay
Basal endothelial cell media, Advanced DMEM (Invitrogen) supplemented with
0.5% FBS, 2mM glutamine, 100units/mL penicillin, and 100µg/mL streptomycin, 25mM
Hepes (Invitrogen), and 100µg/mL heparin (Sigma-Aldrich) was placed in the lower
chamber of a modified Boyden chamber (Corning) separated by a filter with 8µm pores.
Endothelial cells were serum starved overnight with basal endothelial cell media, treated
with experimental reagents for 2 hours, then trypsinized and resuspended in basal media
at 2 x 105 cells/mL. 2 x 104 cells were plated in the upper chamber and allowed to
migrate for 3 hours at 37ºC. The filters were stained with Diff-Quick solution (Baxter,
Miami, FL) and images were taken at RT with a 10× or 20× magnification objective lens
and with a digital camera AxioCAM HRc (Zeiss, Thornwood, CT) mounted on Zeiss
Imager M1 Axio using Zeiss AxioVision Acquisition software (version 4.5). 5 random
images were taken of the filters and the number of cells that migrated across the filter was
counted.

Matrigel tube formation assay
3 x 105 primary lung endothelial cells in 600µL optiMEM with 1% FBS were
plated on top of 600µL of polymerized matrigel in a 12 well plate. Cells were incubated
at 37ºC and 5% CO2 to allow for tube formation. Images were taken at indicated time
points.
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AdCre infection
For in vitro experiments, primary lung endothelial cells from CnBf/f mice were
infected with Cre recombinase adenovirus (Ad5CMVCre; University of Iowa, Gene
Transfer Vector Core) at 500 MOI overnight, followed by PBS wash and media change.
After two passages, cells were assessed for Calcineurin B deletion by immunoblotting for
calcineurin A protein, which degrades in absence of calcineurin B.

DCFDA staining
DCFDA (Abcam) staining was performed following manufacturer’s instructions.
Briefly, cells were treated with drug for 24 hours, then washed and stained with 25µM
DCFDA for 45 minutes at 37ºC. Signal was read at 535nm.

Mitosox and TMRE Staining
Mitosox (Invitrogen) and TMRE (Invitrogen) staining of endothelial cells in vitro
were done following manufacturer’s instructions. Briefly, endothelial cells were washed
with PBS and trypsinized, and then resuspended in calcium and magnesium containing,
phenol red free HBSS (Gibco) supplemented with 0.1µM sodium pyruvate (Sigma) and
5µM Mitosox or 100nM TMRE. Cells were incubated for 10 min (Mitosox) or 20 min
(TMRE) at 37°C in the dark, then flow cytometry was performed using a FACS Canto
flow cytometry machine reading at 610 or 613nm (Mitosox) or 575 nm (TMRE). The
results were analyzed with FlowJo software (TreeStar, Ashland, OR).
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Western blotting
Endothelial cells were scraped from tissue culture dishes and lysed with RIPA
buffer supplemented with a protease inhibitor cocktail (Roche). Whole cell lysates were
separated by SDS-PAGE, transferred to nitrocellulose membrane, and probed with the
following antibodies: p-ERK, total ERK, p-AKT, total AKT (Cell Signaling
Technologies), Calcineurin A (Santa Cruz), β-actin (Sigma). To measure relative gel
densities, band densities were quantified with densitometry analysis using ImageJ
software (NIH) and then normalized to β-actin, or if blotting for a phospho-protein, the
total-protein.
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